Results of intraoperative photodynamic therapy in T1–2 laryngeal cancer ; Результаты применения интраоперационной фотодинамической терапии при раке гортани T1–2

Authors: Spirin P.I., Saidalieva К.A., Sevryukov F.Е., Kapinus V.N., Polkin V.V., Kaprin А.D., Ivanov S.A.

Source: Head and Neck Tumors; Vol 15, No 3 (2025); 43-49 ; Опухоли головы и шеи; Vol 15, No 3 (2025); 43-49 ; 2411-4634 ; 2222-1468

Subject Terms: laryngeal cancer, photodynamic therapy, organ-preserving treatment, laryngeal resection, рак гортани, фотодинамическая терапия, органосохраняющее лечение, резекция гортани

File Description: application/pdf

Relation: https://ogsh.abvpress.ru/jour/article/view/1101/686; https://ogsh.abvpress.ru/jour/article/view/1101

Availability: https://ogsh.abvpress.ru/jour/article/view/1101
https://doi.org/10.17650/2222-1468-2025-15-3-43-49

Combined modality treatment of early breast cancer. Literature review ; Комбинированные методы лечения раннего рака молочной железы. Обзор литературы

Authors: F. Sh. Akhmetzyanov, R. F. Akhmetzyanova, L. E. Ankhimova, E. S. Gorshkova, A. V. Karamanyan, Ф. Ш. Ахметзянов, Р. Ф. Ахметзянова, Л. Е. Анхимова, Е. С. Горшкова, А. В. Караманян

Source: Siberian journal of oncology; Том 22, № 6 (2023); 172-178 ; Сибирский онкологический журнал; Том 22, № 6 (2023); 172-178 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2017-0-31-36

Subject Terms: лучевая терапия, organ-preserving treatment, radiation therapy, органосохраняющее лечение

File Description: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/2846/1191; Bray F., Ferlay J., Laversanne M., Brewster D.H., Gombe Mbalawa C., Kohler B., Piñeros M., Steliarova-Foucher E., Swaminathan R., Antoni S., Soerjomataram I., Forman D. Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. Int J Cancer. 2015; 137(9): 2060–71. doi:10.1002/ijc.29670.; Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М., 2022. 252 с.; Хамаза А.А. Оценка эффективности скринингового исследования в раннем выявлении рака молочной железы. Достижения науки и образования. 2022; 6(86): 90–6.; Алиева Г. С., Корженкова Г.П., Колядина И.В. Возможности маммографии, УЗИ и МРТ в дифференциальной диагностике микрокарцином различных биологических подтипов инвазивного рака молочной железы. Опухоли женской репродуктивной системы. 2020; 16(4): 21–34. doi:10.17650/1994-4098-2020-16-4-12-34.; Нарзиева Д.Ф., Ходжаева Д.И. Рак молочной железы: современные аспекты диагностики. Central Asian Journal of Medical and Natural Science. 2022; 3(4): 99–104.; Рассказова Е.А., Зикиряходжаев А.Д., Каприн А.Д. Онкопластические и органосохраняющие резекции молочной железы при раке. Медицинский алфавит. 2022; 1(5): 42–5. doi:10.33667/2078-5631-2022-5-42-45.; Рожкова Н.И., Прокопенко С.П., Мазо М.Л. Диагностика и лечение рака молочной железы: что изменилось за 20 лет. Доктор. Ру. 2018; 2(146): 35–40.; Ахметзянов Ф.Ш., Шайхутдинов Н.Т., Ахметзянова Р.Ф. Способ первичной пластики при раке молочной железы. Патент РФ № 2171636 C2. Заявл. 17.05.1999; Опубл. 10.08.2001.; Александрова Л.М., Калинина А.М., Ипатов П.В., Грецова О.П., Старинский В.В., Каприн А.Д., Бойцов С.А. Выявление рака молочной железы: состояние проблемы, пути решения. Онкология. Журнал им. П.А. Герцена. 2016; 5(2): 34–9. doi:10.17116/onkolog20165234-39.; Lagendijk M., van Maaren M.C., Saadatmand S., Strobbe L.J.A., Poortmans P.M.P., Koppert L.B., Tilanus-Linthorst M.M.A., Siesling S. Breast conserving therapy and mastectomy revisited: Breast cancer-specifc survival and the infuence of prognostic factors in 129, 692 patients. Int J Cancer. 2018; 142(1): 165–75. doi:10.1002/ijc.31034.; Gwark S., Kim H.J., Kim J., Chung I.Y., Kim H.J., Ko B.S., Lee J.W., Son B.H., Ahn S.H., Lee S.B. Survival After Breast-Conserving Surgery Compared with that After Mastectomy in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Ann Surg Oncol. 2023; 30(5): 2845–53. doi:10.1245/s10434-022-12993-0.; Manirakiza A., Irakoze L., Manirakiza S. Comparison of Survival Outcomes between Early Breast Cancer Patients who Underwent Mastectomy and Patients Treated by Breast Conserving Therapy: A Meta Analysis. East Afr Health Res J. 2022; 6(1): 1–10. doi:10.24248/eahrj.v6i1.672.; Салим Н., Шонус Д.Х., Столбовой А.В. Развитие лучевой терапии рака молочной железы. Онкология. Журнал им. П.А. Герцена. 2017; 6(4): 59–65. doi:10.17116/onkolog20176459-65.; Fisher B., Anderson S., Redmond C.K., Wolmark N., Wickerham D.L., Cronin W.M. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995; 333(22): 1456–61. doi:10.1056/NEJM199511303332203.; Clark R.M., Whelan T., Levine M., Roberts R., Willan A., McCulloch P., Lipa M., Wilkinson R.H., Mahoney L.J. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst. 1996; 88(22): 1659–64. doi:10.1093/jnci/88.22.1659.; van Dongen J.A., Bartelink H., Fentiman I.S., Lerut T., Mignolet F., Olthuis G., van der Schueren E., Sylvester R., Tong D., Winter J., van Zijl K. Randomized clinical trial to assess the value of breast-conserving therapy in Stage I and II breast cancer, EORTC 10801 Trial. Eur J Cancer. 1992; 28 (4–5): 801–5. doi:10.1016/0959-8049(92)90118-L.; Renton S.C., Gazet J.C., Ford H.T., Corbishley C., Sutcliffe R. The importance of the resection margin in conservative surgery for breast cancer. Eur J Surg Oncol. 1996; 22(1): 17–22. doi:10.1016/s0748-7983-(96)91253-6.; Julien J.P., Bijker N., Fentiman I.S., Peterse J.L., Delledonne V., Rouanet P., Avril A., Sylvester R., Mignolet F., Bartelink H., Van Dongen J.A. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: frst results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 2000; 355(9203): 528–33. doi:10.1016/s0140-6736(99)06341-2.; Hughes K.S., Schnaper L.A., Bellon J.R., Cirrincione C.T., Berry D.A., McCormick B., Muss H.B., Smith B.L., Hudis C.A., Winer E.P., Wood W.C. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term followup of CALGB 9343. J Clin Oncol. 2013; 31(19): 2382–7. doi:10.1200/JCO.2012.45.2615.; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); Correa C., McGale P., Taylor C., Wang Y., Clarke M., Davies C., Peto R., Bijker N., Solin L., Darby S. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010; (41):162–77. doi:10.1093/jncimonographs/lgq039.; Чумаченко И.С., Мурашко Р.А., Кешабян А.А., Криворотько П.В., Новиков С.Н. Результаты органосохраняющего лечения рака молочной железы с применением интраоперационной лучевой терапии. Опухоли женской репродуктивной системы. 2021; 17(3): 16–23. doi:10.17650/1994-4098-2021-17-3-16-23.; Kaiser J., Reitsamer R., Kopp P., Gaisberger C., Kopp M., Fischer T., Zehentmayr F., Sedlmayer F., Fastner G. Intraoperative Electron Radiotherapy (IOERT) in the Treatment of Primary Breast Cancer. Breast Care (Basel). 2018; 13(3): 162–7. doi:10.1159/000489637.; Veronesi U., Orecchia R., Maisonneuve P., Viale G., Rotmensz N., Sangalli C., Luini A., Veronesi P., Galimberti V., Zurrida S., Leonardi M.C., Lazzari R., Cattani F., Gentilini O., Intra M., Caldarella P., Ballardini B. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013; 14(13): 1269–77. doi:10.1016/S1470-2045(13)70497-2.; Vaidya J.S., Wenz F., Bulsara M., Tobias J.S., Joseph D.J., Keshtgar M., Flyger H.L., Massarut S., Alvarado M., Saunders C., Eiermann W., Metaxas M., Sperk E., Sütterlin M., Brown D., Esserman L., Roncadin M., Thompson A., Dewar J.A., Holtveg H.M., Pigorsch S., Falzon M., Harris E., Matthews A., Brew-Graves C., Potyka I., Corica T., Williams N.R., Baum M.; TARGIT trialists’ group. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014; 383(9917): 603–13. doi:10.1016/S0140-6736(13)61950-9. Erratum in: Lancet. 2014; 383(9917): 602.; Shah C. Intraoperative Radiation Therapy for Breast Cancer: Are We There Yet? Ann Surg Oncol. 2021; 28(1): 20–21. doi:10.1245/s10434-020-09356-y.; Corsi F., Albasini S., Ciciriello S., Villani L., Truff M., Sevieri M., Sorrentino L. Extensive Intraductal Component in Breast Cancer: What Role in Disease-Free Survival? J Surg Res. 2023; 283: 233–40. doi:10.1016/j.jss.2022.10.094.; Lepomäki M., Karhunen-Enckell U., Tuominen J., Kronqvist P., Oksala N., Murtola T., Roine A. Tumor margins that lead to reoperation in breast cancer: A retrospective register study of 4,489 patients. J Surg Oncol. 2022; 125(4): 577–88. doi:10.1002/jso.26749.; Gage I., Schnitt S.J., Nixon A.J., Silver B., Recht A., Troyan S.L., Eberlein T., Love S.M., Gelman R., Harris J.R., Connolly J.L. Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy. Cancer. 1996; 78(9): 1921–8. doi:10.1002/(sici)1097-0142(19961101)78:93.0.co;2-#.; Smitt M.C., Nowels K.W., Zdeblick M.J., Jeffrey S., Carlson R.W., Stockdale F.E., Goffnet D.R. The importance of the lumpectomy surgical margin status in long-term results of breast conservation. Cancer. 1995; 76(2): 259–67. doi:10.1002/1097-0142(19950715)76:23.0.co;2-2.; Pezner R.D., Wagman L.D., Ben-Ezra J., Odom-Maryon T. Breast conservation therapy: local tumor control in patients with pathologically clear margins who receive 5000 cGy breast irradiation without local boost. Breast Cancer Res Treat. 1994; 32(3): 261–7. doi:10.1007/BF00666003.; Romestaing P., Lehingue Y., Carrie C., Coquard R., Montbarbon X., Ardiet J.M., Mamelle N., Gérard J.P. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol. 1997; 15(3): 963–8. doi:10.1200/JCO.1997.15.3.963.; Старцева Ж.А., Симонов К.А., Слонимская Е.М. Дифференцированный подход к назначению адъювантной лучевой терапии у больных операбельным раком молочной железы. Радиация и риск. 2014; 23(2): 102–11.; Parijs V.H., Cecilia-Joseph E., Gorobets O., Storme G., Adriaenssens N., Heyndrickx B., Verschraegen C., Nguyen N.P., Ridder M.D., Vinh-Hung V. Lung-Heart. Lung-heart toxicity in a randomized clinical trial of hypofractionated image guided radiation therapy for breast cancer. Preprints. 2022; 1. doi:10.20944/preprints202212.0214.v1.; EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group; Bijker N., Meijnen P., Peterse J.L., Bogaerts J., Van Hoorebeeck I., Julien J.P., Gennaro M., Rouanet P., Avril A., Fentiman I.S., Bartelink H., Rutgers E.J. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006; 24(21): 3381–7. doi:10.1200/JCO.2006.06.1366.; Ортабаева Д.Р., Зикиряходжаев А.Д., Рассказова Е.А., Сарибекян Э.К., Каприн А.Д. Отдаленные онкологические результаты органосохраняющего лечения без послеоперационной лучевой терапии у больных ранним раком молочной железы старше 65 лет. Опухоли женской репродуктивной системы. 2022; 18(3): 24–8. doi:10.17650/1994-4098-2022-18-3-24-28.; Liveringhouse C.L., Washington I.R., Diaz R., Jimenez R.B., Harris E.E., Rabinovitch R., Woodward W.A., Torres-Roca J.F., Ahmed K.A. Genomically guided breast radiation therapy: a review of the current data and future directions. Adv Radiat Oncol. 2021; 6(4). doi:10.1016/j.adro.2021.100731.; Chadha M., Ghiassi-Nejad Z., Cate S., Gillego A., Wallach J., Boolbol S.K. Oncotype score as a predictor of local-regional recurrence in early stage breast cancer (BC). Int J Rad Oncol Biol Phys. 2017; 99(2): 54–5. doi:10.1016/j.ijrobp.2017.06.137.; Allen S.G., Speers C., Jagsi R. Tailoring the Omission of Radiotherapy for Early-Stage Breast Cancer Based on Tumor Biology. Semin Radiat Oncol. 2022; 32(3): 198–206. doi:10.1016/j.semradonc.2022.01.006.; The IDEA Study [Internet]. (Individualized Decisions for Endocrine Therapy Alone) [cited 2022 Dec 1]. URL: https://clinicaltrials.gov/ct2/show/NCT02400190.; The PRECISION Trial [Internet] (Profling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer. [cited 2022 Dec 1]. URL: https://www.clinicaltrials.gov/ct2/show/NCT02653755.; Whelan T.J., Smith S., Nielsen T.O., Parpia S., Fyles A.W., Bane A., Liu F., Grimard L., Stevens C., Bowen J., Provencher S., Rakovitch E., Theberge V., Mulligan A.M., Akra M.A., Voduc K.D., Hijal T., Dayes I.S., Pond G.R., Levine M.N. LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC). J Clin Oncol. 2022; 40(17). doi:10.1200/JCO.2022.40.17_suppl.LBA501.; De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) [Internet]. [cited 2022 Dec 1]. URL: https://www.clinicaltrials.gov/ct2/show/NCT04852887.; EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer (EXPERT) [Internet]. [cited 2022 Dec 1]. URL: https://clinicaltrials.gov/ct2/show/NCT02889874.; https://www.siboncoj.ru/jour/article/view/2846

Availability: https://www.siboncoj.ru/jour/article/view/2846
https://doi.org/10.21294/1814-4861-2023-22-6-172-178

Organ-preserving treatment of a patient with a trophoblastic tumor of the placental bed (clinical observation and literature review) ; Органосохраняющее лечение пациентки с трофобластической опухолью плацентарного ложа (клиническое наблюдение и обзор литературы)

Authors: M. N. Tikhonovskaya, A. A. Rumyantsev, L. M. Kappusheva, A. S. Shevchuk, М. Н. Тихоновская, А. А. Румянцев, Л. М. Каппушева, А. С. Шевчук

Source: Surgery and Oncology; Том 14, № 1 (2024); 79-86 ; Хирургия и онкология; Том 14, № 1 (2024); 79-86 ; 2949-5857

Subject Terms: органосохраняющее лечение, fertility sparing treatment

File Description: application/pdf

Relation: https://www.onco-surgery.info/jour/article/view/694/459; Kurman R.J., Scully R.E., Norris H.J. Trophoblastic pseudotumor of the uterus: an exaggerated form of syncytial endometritis simulating a malignant tumor. Cancer 1976;38(3):1214–26. DOI:10.1002/1097-0142(197609)38:33.0.co;2-j; Scully R.E., Young R.H. Trophoblastic pseudotumor: a reappraisal. Am J Surg Pathol 1981;5(1):75–6. DOI:10.1097/00000478-198101000-00010; Behtash N., Karimi Zarchi M. Placental site trophoblastic tumor. J Cancer Res Clin Oncol 2008;134(1):1–6. DOI:10.1007/s00432-007-0208-y.; Мартусова Ю.С., Чекалова М.А., Мещерякова Л.А., Мороз Е.А. Опыт ультразвуковой диагностики трофобластической опухоли плацентарного ложа. Ультразвуковая и функциональная диагностика 2014;4:42–9.; Chiofalo B., Palmara V., Laganà A.S. et al. Fertility sparing strategies in patients affected by placental site trophoblastic tumor. Curr Treat Options Oncol 2017;18(10):58. DOI:10.1007/s11864-017-0502-0; Tsuji Y., Tsubamoto H., Hori M. et al. Case of PSTT treated with chemotherapy followed by open uterine tumor resection to preserve fertility. Gynecol Oncol 2002;87(3):303–7. DOI:10.1006/gyno.2002.6827; Saso S., Haddad J., Ellis P. et al. Placental site trophoblastic tumours and the concept of fertility preservation. BJOG 2012;119(3):369–74. DOI:10.1111/j.1471-0528.2011.03230.x; Jiang S., Zhao J., Shi X. et al. Retrospective analysis of clinical features and fertility outcomes with fertility-sparing treatment of placental site trophoblastic tumor. Gynecol Oncol 2023;171:1–8. DOI:10.1016/j.ygyno.2023.02.002; Shen X., Xiang Y., Guo L. et al. Fertility-preserving treatment in young patients with placental site trophoblastic tumors. Int J Gynecol Cancer 2012;22(5):869–74. DOI:10.1097/IGC.0b013e31824a1bd6; Horowitz N.S., Iskander R.N., Edelman M.R. et al. Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: a Society of Gynecologic Oncology Evidenced-Based Review and Recommendation. Gynecol Oncol 2021;163(3):605–13. DOI:10.1016/j.ygyno.2021.10.003; Chang Y.L., Chang T.C., Hsueh S. et al. Prognostic factors and treatment for placental site trophoblastic tumor – report of 3 cases and analysis of 88 cases. Gynecol Oncol 1999;73(2):216–22. DOI:10.1006/gyno.1999.5344; Lan C., Li Y., He J., Liu J. Placental site trophoblastic tumor: lymphatic spread and possible target markers. Gynecol Oncol 2010;116(3):430–7. DOI:10.1016/j.ygyno.2009.10.56; National Comprechensive Cancer Network. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1489; Seckl M.J., Sebire N.J., Fisher R.A. et al. Gestational trophoblastic disease: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(6):39–50. DOI: 10/1093/annonc/mdt345; Ульрих Е.А., Тюляндина А.С., Проценко С.А., Урманчеева А.Ф. Практические рекомендации по лекарственному лечению злокачественных трофобластических опухолей. Злокачественные опухоли: Практические рекомендации RUSSCO 2022;12:276–86. DOI:10.18027/2224-5057-2022-12-3s2-276-286. Доступно по: https://rosoncoweb.ru/standarts/RUSSCO/2022/2022-15.pdf; Gadducci A., Carinelli S., Guerrieri M.E., Aletti G.D. Placental site trophoblastic tumor and epithelioid trophoblastic tumor: clinical and pathological features, prognostic variables and treatment strategy. Gynecol Oncol 2019;153(3):684–93. DOI:10.1016/j.ygyno.2019.03.011; Feltmate C.M., Genest D.R., Wise L. et al. Placental site trophoblastic tumor: a 17-year experience at the New England Trophoblastic Disease Center. Gynecol Oncol 2001;82(3):415–9. DOI:10.1006/gyno.2001.6265; Zhao J., Lv W.G., Feng F.Z. et al. Placental site trophoblastic tumor: a review of 108 cases and their implications for prognosis and treatment. Gynecol Oncol 2016;142(1):102–8. DOI:10.1016/j.ygyno.2016.05.006; Deng L., Zhang J., Wu T., Lawrie T.A. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev 2013;2013(1):CD005196. DOI:10.1002/14651858.CD005196.pub4; Essel K.G., Bruegl A., Gershenson D.M. et al. Salvage chemotherapy for gestational trophoblastic neoplasia: utility or futility? Gynecol Oncol 2017;146(1):74–80. DOI:10.1016/j.ygyno.2017.04.017; Ajithkumar T.V., Abraham E.K., Rejnishkumar R., Minimole A.L. Placental site trophoblastic tumor. Obstet Gynecol Surv 2003;58(7):484–8. DOI:10.1097/01.OGX.0000077466.40895.32; Numnum T.M., Kilgore L.C., Conner M.G. et al. Fertility sparing therapy in a patient with placental site trophoblastic tumor: a case report. Gynecol Oncol 2006;103(3):1141–3. DOI:10.1016/j.ygyno.2006.07.039; Nie J.C., Chen G.H., Yan A.Q. Liu X S. Postoperative chemotherapy on placental site trophoblastic tumor in early stage: analysis of 60 cases. Eur J Gynaecol Oncol 2017;38(3):431–40.; Schmid P., Nagai Y., Agarwal R. et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. Lancet 2009;374(9683):48–55. DOI:10.1016/S0140-6736(09)60618-8; Pfeffer P.E., Sebire N., Lindsay I. et al. Fertility-sparing partial hysterectomy for placental-site trophoblastic tumour. Lancet Oncol 2007;8(8):744–6. DOI:10.1016/S1470-2045(07)70243-7; Loret de Mola J.R., Goldfarb J.M. Reproductive performance of patients after gestational trophoblastic disease. Semi Oncol 1995;22(2):193–7.; Гордеев С.С., Магаррамова З.Н., Мышляков В.С. и др. Редкие злокачественные новообразования в практике онкопроктолога: ретроспективный анализ опыта клиники за 20 лет. Поволжский онкологический вестник 2022;13(4):31–7.; Гордеев С.С., Рыбаков Е.Г., Карачун А.М. и др. Выбор оптимального объема хирургического лечения при аноректальной меланоме: ретроспективный анализ реестра Российского общества специалистов по колоректальному раку. Тазовая хирургия и онкология 2022;12(4):11–8. DOI:10.17650/2686-9594-2022-12-4-11-18

Availability: https://www.onco-surgery.info/jour/article/view/694
https://doi.org/10.17650/2949-5857-2024-14-1-79-86

Current state of the placenta accreta spectrum issue: prospects for organ-preserving treatment ; Современное состояние вопроса placenta accreta spectrum: перспективы органосохраняющего лечения

Authors: M. D. Voronina, D. A. Dolgiev, R. A. Dolgieva, A. S. Mirovaeva, Z. F. Garaeva, Yu. K. Ivanova, I. V. Sarapultsev, E. I. Turdieva, V. A. Rakov, V. K. Kuklina, A. E. Manelov, K. Kh. Khalilova, М. Д. Воронина, Д. А. Долгиев, Р. А. Долгиева, А. С. Мироваева, З. Ф. Гараева, Ю. К. Иванова, И. В. Сарапульцев, Е. И. Турдиева, В. А. Раков, В. К. Куклина, А. Е. Манелов, К. Х. Халилова

Source: Obstetrics, Gynecology and Reproduction; Vol 19, No 1 (2025); 82-96 ; Акушерство, Гинекология и Репродукция; Vol 19, No 1 (2025); 82-96 ; 2500-3194 ; 2313-7347

Subject Terms: органосохраняющее ведение, PAS, hysterectomy, organ-preserving treatment, organ-preserving management, гистерэктомия, органосохраняющее лечение

File Description: application/pdf

Relation: https://www.gynecology.su/jour/article/view/2258/1292; Сюндюкова Е.Г., Чуланова Ю.С., Сашенков С.Л. и др. Предлежание и врастание плаценты: вопросы диагностики и акушерской тактики. Российский вестник акушера-гинеколога. 2022;22(3):12–20. https://doi.org/10.17116/rosakush20222203112.; Mogos M.F., Salemi J.L., Ashley M. et al. Recent trends in placenta accreta in the United States and its impact on maternal-fetal morbidity and healthcare-associated costs, 1998–2011. J Matern Fetal Neonatal Med. 2016;29(7):1077–82. https://doi.org/10.3109/14767058.2015.1034103.; Барановская Е.И. Этиология и диагностика placenta accreta. Российский вестник акушера-гинеколога. 2020;20(3):24–8. https://doi.org/10.17116/rosakush20202003124.; Лебеденко Е.Ю., Беспалая А.В., Феоктистова Т.Е., Рымашевский М.А. Анализ мировых трендов уровня кесарева сечения с использованием классификации Робсона. Медицинский вестник Юга России. 2021;12(2):16–21. https://doi.org/10.21886/2219-8075-2021-12-2-16-21.; Silver R.M., Branch D.W. Placenta accreta spectrum. N Engl J Med. 2018;378(16):1529–36. https://doi.org/10.1056/NEJMcp1709324.; Einerson B.D., Gilner J.B., Zuckerwise L.C. Placenta accreta spectrum. Obstet Gynecol. 2023;142(1):31–50. https://doi.org/10.1097/AOG.0000000000005229.; Ernst L.M., Linn R.L., Minturn L., Miller E.S. Placental pathologic associations with morbidly adherent placenta: potential insights into pathogenesis. Pediatr Dev Pathol. 2017;20(5):387–93. https://doi.org/10.1177/1093526617698600.; Jauniaux E., Bhide A., Kennedy A. et al.; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Prenatal diagnosis and screening. Int J Gynaecol Obstet. 2018;140(3):274–80. https://doi.org/10.1002/ijgo.12408.; Jauniaux E., Ayres-de-Campos D., Langhoff-Roos J. et al. FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2019;146(1):20–4. https://doi.org/10.1002/ijgo.12761.; Yu F.N.Y., Leung K.Y. Antenatal diagnosis of placenta accreta spectrum (PAS) disorders. Best Pract Res Clin Obstet Gynaecol. 2021;72:13–24. https://doi.org/10.1016/j.bpobgyn.2020.06.010.; Carusi D.A., Fox K.A., Lyell D.J. et al. Placenta accreta spectrum without placenta previa. Obstet Gynecol. 2020;136(3):458–65. https://doi.org/10.1097/AOG.0000000000003970.; Sugai S., Yamawaki K., Sekizuka T. et al. Pathologically diagnosed placenta accreta spectrum without placenta previa: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2023;5(8):101027. https://doi.org/10.1016/j.ajogmf.2023.101027.; Committee on Obstetric Practice. Committee opinion no. 529: placenta accreta. Obstet Gynecol. 2012;120(1):207–11. https://doi.org/10.1097/AOG.0b013e318262e340.; Jauniaux E., Collins S., Burton G.J. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet Gynecol. 2018;218(1):75–87. https://doi.org/10.1016/j.ajog.2017.05.067.; Laoreti A., Thilaganathan B., Agten A.K. et al. Placental thickness in the lower uterine segment and invasive placentation: Will the promise live up? Acta Obstet Gynecol Scand. 2019;98(2):266. https://doi.org/10.1111/aogs.13460.; Familiari A., Liberati M., Lim P. et al. Diagnostic accuracy of magnetic resonance imaging in detecting the severity of abnormal invasive placenta: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2018;97(5):507–20. https://doi.org/10.1111/aogs.13258.; Palacios-Jaraquemada J.M., Bruno C.H., Martín E. MRI in the diagnosis and surgical management of abnormal placentation. Acta Obstet Gynecol Scand. 2013;92(4):392–7. https://doi.org/10.1111/j.1600-0412.2012.01527.x.; D'Antonio F., Palacios-Jaraquemada J., Lim P.S. et al. Counseling in fetal medicine: evidence-based answers to clinical questions on morbidly adherent placenta. Ultrasound Obstet Gynecol. 2016;47(3):290–301. https://doi.org/10.1002/uog.14950.; Collins S.L., Alemdar B., van Beekhuizen H.J. et al.; International Society for Abnormally Invasive Placenta (IS-AIP). Evidence-based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive Placenta. Am J Obstet Gynecol. 2019;220(6):511–26. https://doi.org/10.1016/j.ajog.2019.02.054.; Allen L., Jauniaux E., Hobson S. et al. FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Nonconservative surgical management. Int J Gynaecol Obstet. 2018;140(3):281–90. https://doi.org/10.1002/ijgo.12409.; Jauniaux E., Bhide A. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017;217(1):27–36. https://doi.org/10.1016/j.ajog.2017.02.050.; Fitzpatrick K.E., Sellers S., Spark P. et al. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study. BJOG. 2014;121(1):62–70. https://doi.org/10.1111/1471-0528.12405.; Nieto-Calvache A.J., Palacios-Jaraquemada J.M., Osanan G. et al. Latin American group for the study of placenta accreta spectrum. Lack of experience is a main cause of maternal death in placenta accreta spectrum patients. Acta Obstet Gynecol Scand. 2021;100(8):1445–53. https://doi.org/10.1111/aogs.14163.; Overton E., Wen T., Friedman A.M. et al. Outcomes associated with peripartum hysterectomy in the setting of placenta accreta spectrum disorder. Am J Obstet Gynecol MFM. 2023;5(12):101–174. https://doi.org/10.1016/j.ajogmf.2023.101174.; Bailit J.L., Grobman W.A., Rice M.M. et al.; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Morbidly adherent placenta treatments and outcomes. Obstet Gynecol. 2015;125(3):683–9. https://doi.org/10.1097/AOG.0000000000000680.; Angstmann T., Gard G., Harrington T. et al. Surgical management of placenta accreta: a cohort series and suggested approach. Am J Obstet Gynecol. 2010;202(1):38.e1-9. https://doi.org/10.1016/j.ajog.2009.08.037.; Shamshirsaz A.A., Fox K.A., Salmanian B. et al. Maternal morbidity in patients with morbidly adherent placenta treated with and without a standardized multidisciplinary approach. Am J Obstet Gynecol. 2015;212(2):218.1–9. https://doi.org/10.1016/j.ajog.2014.08.019.; Eller A.G., Porter T.F., Soisson P., Silver R.M. Optimal management strategies for placenta accreta. BJOG. 2009;116(5):648–54. https://doi.org/10.1111/j.1471-0528.2008.02037.x.; Warshak C.R., Ramos G.A., Eskander R. et al. Effect of predelivery diagnosis in 99 consecutive cases of placenta accreta. Obstet Gynecol. 2010;115(1):65–9. https://doi.org/10.1097/AOG.0b013e3181c4f12a.; Sentilhes L., Kayem G., Mattuizzi A. Conservative approach: Intentional retention of the placenta. Best Pract Res Clin Obstet Gynaecol. 2021;72:52–66. https://doi.org/10.1016/j.bpobgyn.2020.07.010.; Schumann E.A. Pathology of the third stage of labor with especial reference to the placental element. Med Rec Ann. 1940;151:381–4.; Sentilhes L., Deneux-Tharaux C., Seco A., Kayem G. 4: Conservative management versus cesarean hysterectomy for placenta accreta spectrum; the PACCRETA prospective population-based study. Am J Obstet Gynecol. 2020;222(1):S3–S4.; Sentilhes L., Seco A., Azria E. et al.; PACCRETA Study Group. Conservative management or cesarean hysterectomy for placenta accreta spectrum: the PACCRETA prospective study. Am J Obstet Gynecol. 2022;226(6):839.e1– 839.e24. https://doi.org/10.1016/j.ajog.2021.12.013.; Sentilhes L., Seco A., Kayem G., Deneux-Tharaux C. Postdischarge outcomes of readmitted women included in the PACCRETA study. Am J Obstet Gynecol. 2022;227(5):795–8. https://doi.org/10.1016/j.ajog.2022.06.042.; Amsalem H., Kingdom J.C.P., Farine D. et al. Planned caesarean hysterectomy versus "conserving" caesarean section in patients with placenta accreta. J Obstet Gynaecol Can. 2011;33(10):1005–10. https://doi.org/10.1016/S1701-2163(16)35049-6.; Kutuk M.S., Ak M., Ozgun M.T. Leaving the placenta in situ versus conservative and radical surgery in the treatment of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2018;140(3):338–44. https://doi.org/10.1002/ijgo.12308.; Bouvier A., Sentilhes L., Thouveny F. et al. Planned caesarean in the interventional radiology cath lab to enable immediate uterine artery embolization for the conservative treatment of placenta accreta. Clin Radiol. 2012;67(11):1089–94. https://doi.org/10.1016/j.crad.2012.04.001.; Sentilhes L., Kayem G., Chandraharan E. et al; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Conservative management. Int J Gynaecol Obstet. 2018;140(3):291–8. https://doi.org/10.1002/ijgo.12410.; Soyer P., Sirol M., Fargeaudou Y. et al. Placental vascularity and resorption delay after conservative management of invasive placenta: MR imaging evaluation. Eur Radiol. 2013;23(1):262–71. https://doi.org/10.1007/s00330-012-2573-4.; Pineles B.L., Coselli J., Ghorayeb T. et al. Leaving the placenta in situ in placenta accreta spectrum disorders: a single-center case series. Am J Perinatol. 2024;41(S 01):е420–е429. https://doi.org/10.1055/a-1885-1942.; Sentilhes L., Ambroselli C., Kayem G. et al. Maternal outcome after conservative treatment of placenta accreta. Obstet Gynecol. 2010;115(3):526–34. https://doi.org/10.1097/AOG.0b013e3181d066d4.; Legendre G., Zoulovits F.J., Kinn J. et al. Conservative management of placenta accreta: hysteroscopic resection of retained tissues. J Minim Invasive Gynecol. 2014;21(5):910–3. https://doi.org/10.1016/j.jmig.2014.04.004.; Барановская Е.И. Предотвращение массивного кровотечения при placenta accreta. Российский вестник акушера-гинеколога. 2021;21(1):84–7. https://doi.org/10.17116/rosakush20212101184.; Куликов И.А., Доброхотова Ю.Э., Артемьева К.А. и др. Современный взгляд на тактику лечения беременных с патологическим прикреплением и предлежанием плаценты (обзор литературы). Проблемы репродукции. 2023;29(2):42–50. https://doi.org/10.17116/repro20232902142.; Taylor F.B., Toh C.H., Hoots W.K. et al.; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327–30.; Asakura H., Takahashi H., Uchiyama T. et al.; DIC subcommittee of the Japanese Society on Thrombosis and Hemostasis. Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2016;14:42. https://doi.org/10.1186/s12959-016-0117-x.; Singh N., Sethi A. Endometritis – diagnosis, treatment and its impact on fertility – a scoping review. JBRA Assist Reprod. 2022;26(3):538–46. https://doi.org/10.5935/1518-0557.20220015.; Калинкина О.Б., Тезиков Ю.В., Липатов И.С. и др. Опыт органосохраняющей тактики ведения при врастании плаценты. Медико-фармацевтический журнал "Пульс". 2023;25(6):37–42. https://doi.org/10.26787/nydha-2686-6838-2023-25-6-37-42.; Grover B., Einerson B.D., Keenan K.D. et al. Patient-reported health outcomes and quality of life after peripartum hysterectomy for placenta accreta spectrum. Am J Perinatol. 2022;39(3):281–7. https://doi.org/10.1055/s-0040-1715465.; Sentilhes L., Kayem G., Silver R.M. Conservative management of placenta accreta spectrum. Clin Obstet Gynecol. 2018;61(4):783–94. https://doi.org/10.1097/GRF.0000000000000395.; Dahl C.M., Turok D., Heuser C.C. et al. Strategies for obstetricians and gynecologists to advance reproductive autonomy in a post-Roe landscape. Am J Obstet Gynecol. 2024;230(2):226–34. https://doi.org/10.1016/j.ajog.2023.07.055.; Einerson B.D., Watt M.H., Sartori B. et al. Lived experiences of patients with placenta accreta spectrum in Utah: a qualitative study of semistructured interviews. BMJ Open. 2021;11(11):e052766. https://doi.org/10.1136/bmjopen-2021-052766.; Bartels H.C., Horsch A., Cooney N. et al. Living with a diagnosis of Placenta Accreta Spectrum: Mothers' and Fathers' experience of the antenatal journey and the birth. PLoS One. 2023;18(5):e0286082. https://doi.org/10.1371/journal.pone.0286082.; Bartels H.C., Horsch A., Cooney N. et al. Living beyond placenta accreta spectrum: parent's experience of the postnatal journey and recommendations for an integrated care pathway. BMC Pregnancy Childbirth. 2022;22(1):397. https://doi.org/10.1186/s12884-022-04726-8.; Shainker S.A., Cornely R.M., Astake R., Hacker M.R. Patient perception of care, outcomes, and consequences from placenta accreta spectrum: a survey-based study. Am J Perinatol. 2024;41(S 01):е486–е493. https://doi.org/10.1055/a-1905-5079.; Bartels H.C., Lalor J.G., Walsh D. et al. Anesthesia and postpartum pain management for placenta accreta spectrum: the patient perspective and recommendations for care. Int J Gynaecol Obstet. 2024;164(3):992–1000. https://doi.org/10.1002/ijgo.15125.; Abi Habib P., Goetzinger K., Turan O.M. Placenta accreta spectrum conservative management and coagulopathy: case series and systematic review. Ultrasound Obstet Gynecol. 2024;63(6):731–7. https://doi.org/10.1002/uog.27547.; Marcellin L., Delorme P., Bonnet M.P. et al. Placenta percreta is associated with more frequent severe maternal morbidity than placenta accreta. Am J Obstet Gynecol. 2018;219(2):193.e1–193.e9. https://doi.org/10.1016/j.ajog.2018.04.049.; Pather S., Strockyj S., Richards A. et al. Maternal outcome after conservative management of placenta percreta at caesarean section: a report of three cases and a review of the literature. Aust N Z J Obstet Gynaecol. 2014;54(1):84–7. https://doi.org/10.1111/ajo.12149.; Clausen C., Lönn L., Langhoff-Roos J. Management of placenta percreta: a review of published cases. Acta Obstet Gynecol Scand. 2014;93(2):138– 43. https://doi.org/10.1111/aogs.12295.; Youssefzadeh A.C., Matsuzaki S., Mandelbaum R.S. et al. Trends, characteristics, and outcomes of conservative management for placenta percreta. Arch Gynecol Obstet. 2022;306(3):913–20. https://doi.org/10.1007/s00404-021-06384-1.; Sentilhes L., Kayem G., Deneux-Tharaux C. Conservative management or cesarean hysterectomy for placenta percreta? A subgroup analysis of the PACCRETA study is needed. Am J Obstet Gynecol. 2022;227(1):117–8. https://doi.org/10.1016/j.ajog.2022.01.029.; Shamshirsaz A.A., Fox K.A., Erfani H. et al. Multidisciplinary team learning in the management of the morbidly adherent placenta: outcome improvements over time. Am J Obstet Gynecol. 2017;216(6):612.e1– 612.e5. https://doi.org/10.1016/j.ajog.2017.02.016.; Erfani H., Fox K.A., Clark S.L. et al. Maternal outcomes in unexpected placenta accreta spectrum disorders: single-center experience with a multidisciplinary team. Am J Obstet Gynecol. 2019;221(4):337.e1–337.e5. https://doi.org/10.1016/j.ajog.2019.05.035.; Fitzgerald G.D., Newton J.M., Atasi L. et al. Pan-American Society for Placenta Accreta Spectrum. Placenta accreta spectrum care infrastructure: an evidence-based review of needed resources supporting placenta accreta spectrum care. Am J Obstet Gynecol MFM. 2024;6(1):101229. https://doi.org/10.1016/j.ajogmf.2023.101229.; Silver R.M., Fox K.A., Barton J.R. et al. Center of excellence for placenta accreta. Am J Obstet Gynecol. 2015;212(5):561–8. https://doi.org/10.1016/j.ajog.2014.11.018.; Nawrocki P.S., Levy M., Tang N. et al. Interfacility transport of the pregnant patient: a 5-year retrospective review of a Single Critical Care Transport Program. Prehosp Emerg Care. 2019;23(3):377–84. https://doi.org/10.1080/10903127.2018.1519005.; Sentilhes L., Kayem G., Ambroselli C. et al. Fertility and pregnancy outcomes following conservative treatment for placenta accreta. Hum Reprod. 2010;25(11):2803–10. https://doi.org/10.1093/humrep/deq239.; Salomon L.J., de Tayrac R., Castaigne-Meary V. et al. Fertility and pregnancy outcome following pelvic arterial embolization for severe postpartum haemorrhage. A cohort study. Hum Reprod. 2003;18(4):849–52. https://doi.org/10.1093/humrep/deg168.; Provansal M., Courbiere B., Agostini A. et al. Fertility and obstetric outcome after conservative management of placenta accreta. Int J Gynaecol Obstet. 2010;109(2):147–50. https://doi.org/10.1016/j.ijgo.2009.12.011.; Zhao H., Liu C., Fu H. et al. Subsequent pregnancy outcomes and risk factors following conservative treatment for placenta accreta spectrum: a retrospective cohort study. Am J Obstet Gynecol MFM. 2023;5(12):101189. https://doi.org/10.1016/j.ajogmf.2023.101189.; Kabiri D., Hants Y., Shanwetter N. et al. Outcomes of subsequent pregnancies after conservative treatment for placenta accreta. Int J Gynaecol Obstet. 2014;127(2):206–10. https://doi.org/10.1016/j.ijgo.2014.05.013.; Baldwin H.J., Nippita T.A., Torvaldsen S. et al. Outcomes of subsequent births after placenta accreta spectrum. Obstet Gynecol. 2020;136(4):745– 55. https://doi.org/10.1097/AOG.0000000000004051.; Roeca C., Little S.E., Carusi D.A. Pathologically diagnosed placenta accreta and hemorrhagic morbidity in a subsequent pregnancy. Obstet Gynecol. 2017;129(2):321–6. https://doi.org/10.1097/AOG.0000000000001843.; Javinani A., Qaderi S., Hessami K. et al. Delivery outcomes in the subsequent pregnancy following the conservative management of placenta accreta spectrum disorder: a systematic review and metaanalysis. Am J Obstet Gynecol. 2024;230(5):485–492.e7. https://doi.org/10.1016/j.ajog.2023.10.047.; https://www.gynecology.su/jour/article/view/2258

Availability: https://www.gynecology.su/jour/article/view/2258
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2024.571

Trimodal organ‑preserving treatment of muscle‑invasive bladder cancer ; Тримодальная органосохраняющая терапия мышечно-инвазивного рака мочевого пузыря

Authors: A. V. Troianov, I. O. Dementev, I. N. Zaborsky, V. S. Chaykov, O. B. Karyakin, Yu. V. Gumenetskaya, А. В. Троянов, И. О. Дементьев, И. Н. Заборский, В. С. Чайков, О. Б. Карякин, Ю. В. Гуменецкая

Source: Research and Practical Medicine Journal; Том 10, № 1 (2023); 111-125 ; Research'n Practical Medicine Journal; Том 10, № 1 (2023); 111-125 ; 2410-1893 ; 10.17709/2410-1893-2023-10-1

Subject Terms: комбинированное лечение, organ-preserving treatment, trimodal therapy, combined treatment, органосохраняющее лечение, тримодальная терапия

File Description: application/pdf

Relation: https://www.rpmj.ru/rpmj/article/view/864/543; Prout GR, Marshall VF. The prognosis with untreated bladder tumors. Cancer. 1956;9(3):551–8.; Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol. 2011 Jan;185(1):72–78. https://doi.org/10.1016/j.juro.2010.09.015; American Cancer Society. Cancer Facts and Figures 2016. Atlanta: American Cancer Society; 2016. https://doi.org/10.3322/caac.21332; Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009 Jan;55(1):164–174. https://doi.org/10.1016/j.eururo.2008.07.031; Gandaglia G, Varda B, Sood A, Pucheril D, Konijeti R, Sammon JD, et al. Short‑term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database. Can Urol Assoc J. 2014 Sep;8(9‑10):E681–687. https://doi.org/10.5489/cuaj.2069; Shimko MS, Tollefson MK, Umbreit EC, Farmer SA, Blute ML, Frank I. Long‑term complications of conduit urinary diversion. J Urol. 2011 Feb;185(2):562–567. https://doi.org/10.1016/j.juro.2010.09.096; NCCN Clinical Practice Guildelines in Oncology: Bladder Cancer. Version 1.2022. February 11, 2022. National Comprehensive Cancer Network, Inc. Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf; EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2022. ISBN 978‑94‑92671‑16‑5.; Smith ZL, Christodouleas JP, Keefe SM, Malkowicz SB, Guzzo TJ. Bladder preservation in the treatment of muscle‑invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int. 2013 Jul;112(1):13–25. https://doi.org/10.1111/j.1464‑410x.2012.11762.x; Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, et al.; International Consultation on Urologic Disease‑European Association of Urology Consultation on Bladder Cancer 2012. ICUD‑EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle‑invasive urothelial carcinoma of the bladder. Eur Urol. 2013 Jan;63(1):45–57. https://doi.org/10.1016/j.eururo.2012.08.009; Biagioli MC, Fernandez DC, Spiess PE, Wilder RB. Primary bladder preservation treatment for urothelial bladder cancer. Cancer Control. 2013 Jul;20(3):188–199. https://doi.org/10.1177/107327481302000307; Herr HW. Transurethral resection of muscle‑invasive bladder cancer: 10‑year outcome. J Clin Oncol. 2001 Jan 1;19(1):89–93. https://doi.org/10.1200/jco.2001.19.1.89; Holmäng S, Hedelin H, Anderström C, Johansson SL. Long‑term followup of all patients with muscle invasive (stages T2, T3 and T4) bladder carcinoma in a geographical region. J Urol. 1997 Aug;158(2):389–392.; Solsona E, Iborra I, Collado A, Rubio‑Briones J, Casanova J, Calatrava A. Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol. 2010 Aug;184(2):475–480. https://doi.org/10.1016/j.juro.2010.04.008; Volkmer BG, Kuefer R, Bartsch G Jr, Straub M, de Petriconi R, Gschwend JE, Hautmann RE. Effect of a pT0 cystectomy specimen without neoadjuvant therapy on survival. Cancer. 2005 Dec 1;104(11):2384–2391. https://doi.org/10.1002/cncr.21475; Milosevic M, Gospodarowicz M, Zietman A, Abbas F, Haustermans K, Moonen L, Rödel C, Schoenberg M, Shipley W. Radiotherapy for bladder cancer. Urology. 2007 Jan;69(1 Suppl):80–92. https://doi.org/10.1016/j.urology.2006.05.060; Søndergaard J, Holmberg M, Jakobsen AR, Agerbæk M, Muren LP, Høyer M. A comparison of morbidity following conformal versus intensity‑modulated radiotherapy for urinary bladder cancer. Acta Oncol. 2014 Oct;53(10):1321–1328. https://doi.org/10.3109/0284186x.2014.928418; Tonoli S, Bertoni F, De Stefani A, Vitali E, De Tomasi D, Caraffini B, et al. Radical radiotherapy for bladder cancer: retrospective analysis of a series of 459 patients treated in an Italian institution. Clin Oncol (R Coll Radiol). 2006 Feb;18(1):52–59. https://doi.org/10.1016/j.clon.2005.06.015; Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, et al. Long‑term outcomes of selective bladder preservation by combined‑modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012 Apr;61(4):705–711. https://doi.org/10.1016/j.eururo.2011.11.010; Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL. Long‑term outcomes in patients with muscle‑invasive bladder cancer after selective bladder‑preserving combined‑modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014 Dec 1;32(34):3801–3809. https://doi.org/10.1200/jco.2014.57.5548; James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al.; BC2001 Investigators. Radiotherapy with or without chemotherapy in muscle‑invasive bladder cancer. N Engl J Med. 2012 Apr 19;366(16):1477–1488. https://doi.org/10.1056/nejmoa1106106; Tarin TV, Power NE, Ehdaie B, Sfakianos JP, Silberstein JL, Savage CJ, et al. Lymph node‑positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity. Eur Urol. 2012 May;61(5):1025–1030. https://doi.org/10.1016/j.eururo.2012.01.049; Huddart RA, Hall E, Hussain SA, Jenkins P, Rawlings C, Tremlett J, et al. Randomized noninferiority trial of reduced high‑dose volume versus standard volume radiation therapy for muscle‑invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):261–269. https://doi.org/10.1016/j.ijrobp.2013.06.2044. Erratum in: Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):860; Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, Shariat SF, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W. Critical analysis of bladder sparing with trimodal therapy in muscle‑invasive bladder cancer: a systematic review. Eur Urol. 2014 Jul;66(1):120–137. https://doi.org/10.1016/j.eururo.2014.02.038; Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU. RTOG 97‑06: initial report of a phase I‑II trial of selective bladder conservation using TURBT, twice‑daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):665–672. https://doi.org/10.1016/s0360‑3016(03)00718‑1; Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ 3rd, Toonkel LM, et al. Phase I‑II RTOG study (99‑06) of patients with muscle‑invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice‑daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009 Apr;73(4):833–837. https://doi.org/10.1016/j.urology.2008.09.036; Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, et al. Transurethral surgery and twice‑daily radiation plus paclitaxel‑cisplatin or fluorouracil‑cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomized multicentre phase 2 trial. Lancet Oncol. 2013 Aug;14(9):863–872. https://doi.org/10.1016/s1470‑2045(13)70255‑9; Kaufman DS, Winter KA, Shipley WU, Heney NM, Chetner MP, Souhami L, et al. The initial results in muscle‑invading bladder cancer of RTOG 95‑06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5‑fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist. 2000;5(6):471–476. https://doi.org/10.1634/theoncologist.5‑6‑471; Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996 Nov;14(11):2901–2907. https://doi.org/10.1200/jco.1996.14.11.2901; Azria D, Riou O, Rebillard X, Thezenas S, Thuret R, Fenoglietto P, Pouessel D, Culine S. Combined chemoradiation therapy with twice‑weekly gemcitabine and cisplatin for organ preservation in muscle‑invasive bladder cancer: long‑term results of a phase 1 trial. Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):853–859. https://doi.org/10.1016/j.ijrobp.2013.11.016; Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 1996 Jan;14(1):119–126. https://doi.org/10.1200/jco.1996.14.1.119; Tester W, Porter A, Asbell S, Coughlin C, Heaney J, Krall J, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85‑12. Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):783–790. https://doi.org/10.1016/0360‑3016(93)90306‑g; Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89‑03. J Clin Oncol. 1998 Nov;16(11):3576–3583. https://doi.org/10.1200/jco.1998.16.11.3576; De Santis M, Bachner M, Cerveny M, Kametriser G, Steininger T, Königsberg R, et al. Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial. Ann Oncol. 2014 Sep;25(9):1789–1794. https://doi.org/10.1093/annonc/mdu209; von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000 Sep;18(17):3068–3077. https://doi.org/10.1200/jco.2000.18.17.3068; Mitin T, George A, Zietman AL, Heney NM, Kaufman DS, Uzzo RG, et al. Long‑Term Outcomes Among Patients Who Achieve Complete or Near‑Complete Responses After the Induction Phase of Bladder‑Preserving Combined‑Modality Therapy for Muscle‑Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233. Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):67–74. https://doi.org/10.1016/j.ijrobp.2015.09.030; Гуменецкая Ю. В., Попов А. М., Карякин О. Б., Мардынский Ю. С., Гулидов И. А. Результаты комбинированного лечения (трансуретральной резекции опухоли с последующей дистанционной лучевой терапией) у больных мышечно‑инвазивным раком мочевого пузыря. Сибирский онкологический журнал. 2012;50(2):6–10.; Гуменецкая Ю. В., Попов А. М., Карякин О. Б. Анализ осложнений комплексного органосохраняющего лечения больных мышечно‑инвазивным раком мочевого пузыря. Актуальные вопросы диагностики и лечения местно‑распространенного и метастатического рака почки, мочевого пузыря и предстательной железы. Материалы конференции онкоурологов стран СНГ, Украина, Киев, 2012, с. 33–34.; Гуменецкая Ю.В.,Попов А.М.,Карякин О.Б.Отдаленные результаты комплексного органосохраняющего лечения больных мышечно‑инвазивным раком мочевого пузыря. Актуальные вопросы диагностики и лечения местно‑распространенного и метастатического рака почки, мочевого пузыря и предстательной железы: материалы конференции онкоурологов стран СНГ, Украина, Киев, 2012, с. 34.; Карякин О. Б., Мардынский Ю. С., Гришин Г. Н., Сахарова О. В., Теплякова Ю. В. Комбинированное лечение местнораспространенного рака мочевого пузыря. Урология и нефрология. 1996;1:17–19.; Карякин О. Б. Органосохранная тактика при инвазивном раке мочевого пузыря: «за» и «против». Практическая онкология. 2003;4(4):252–254.; Карякин О. Б., Сафиуллин К. Н., Полтораков А. М., Теплякова Ю. В. Комбинированное лечение местнораспространенного рака мочевого пузыря. Медицинская радиология. 1992;37(11–12):12–13.; Karyakin O, Popov A. Conservative treatment of invasive bladder cancer. European Urology Supplements. 2004;3(2):178.; Гуменецкая Ю. В., Попов А. М., Карякин О. Б., Гулидов И. А. Результаты химиолучевого лечения мышечно‑инвазивного рака мочевого пузыря. Сибирский онкологический журнал. 2013;6:9–13.; Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long‑term results in 1,054 patients. J Clin Oncol. 2001 Feb 1;19(3):666–675. https://doi.org/10.1200/jco.2001.19.3.666; Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003 Aug 28;349(9):859–866. https://doi.org/10.1056/nejmoa022148. Erratum in: N Engl J Med. 2003 Nov 6;349(19):1880; Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, Reuter V. Cystectomy for bladder cancer: a contemporary series. J Urol. 2001 Apr;165(4):1111–1116.; Gloeckler‑Ries LA, Young JL, Keel GE, et al. (eds). SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988‑2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07‑6215, Bethesda, MD, 2007.; Cahn DB, Handorf E, Nordsiek M, et al. Contemporary Utilization Trends and Survival Outcomes in Patients Undergoing Radical Cystectomy and Bladder Preservation Therapy for Muscle Invasive Bladder Cancer. J Clin Oncol. 2016;34(suppl 2S, abstr 387). https://doi.org/10.1002/cncr.30900; Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, et al. Long‑term Outcomes After Bladder‑preserving Tri‑modality Therapy for Patients with Muscle‑invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017 Jun;71(6):952–960. https://doi.org/10.1016/j.eururo.2016.12.020; Miyamoto D, Drumm M, Clayman RH. Outcomes and tolerability of selective bladder preservation by combined modality therapy for invasive bladder cancer in elderly patients. J Clin Oncolю 2017;35 (suppl 6S; abstract 316). https://doi.org/10.1200/jco.2017.35.6_suppl.316; Takayanagi A, Masumori N, Takahashi A, Takagi Y, Tsukamoto T. Upper urinary tract recurrence after radical cystectomy for bladder cancer: incidence and risk factors. Int J Urol. 2012 Mar;19(3):229–233. https://doi.org/10.1111/j.1442‑2042.2011.02916.x; Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, Sandler HM. Late pelvic toxicity after bladder‑sparing therapy in patients with invasive bladder cancer: RTOG 89‑03, 95‑06, 97‑06, 99‑06. J Clin Oncol. 2009 Sep 1;27(25):4055–4061. https://doi.org/10.1200/jco.2008.19.5776; Zietman AL, Sacco D, Skowronski U, Gomery P, Kaufman DS, Clark JA, Talcott JA, Shipley WU. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long‑term survivors. J Urol. 2003 Nov;170(5):1772–1776. https://doi.org/10.1097/01.ju.0000093721.23249.c3; Ramani VA, Maddineni SB, Grey BR, Clarke NW. Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis. Eur Urol. 2010 Jun;57(6):1058–1063. https://doi.org/10.1016/j.eururo.2009.12.002; Eswara JR, Efstathiou JA, Heney NM, Paly J, Kaufman DS, McDougal WS, et al. Complications and long‑term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol. 2012 Feb;187(2):463–468. https://doi.org/10.1016/j.juro.2011.09.159; Iwai A, Koga F, Fujii Y, Masuda H, Saito K, Numao N, Sakura M, Kawakami S, Kihara K. Perioperative complications of radical cystectomy after induction chemoradiotherapy in bladder‑sparing protocol against muscle‑invasive bladder cancer: a single institutional retrospective comparative study with primary radical cystectomy. Jpn J Clin Oncol. 2011 Dec;41(12):1373–1379. https://doi.org/10.1093/jjco/hyr150; Kang JJ,Steinberg ML,Kupelian P,Alexander S,King CR.Whole Versus Partial Bladder Radiation:Use of an Image‑guided Hypofractionated IMRT Bladder‑preservation Protocol.Am J Clin Oncol.2018 Feb;41(2):107–114.https://doi.org/10.1097/coc.0000000000000237; https://www.rpmj.ru/rpmj/article/view/864

Availability: https://www.rpmj.ru/rpmj/article/view/864
https://doi.org/10.17709/2410-1893-2023-10-1-10

Clinical experience of combined organ-preserving treatment of laryngopharyngeal cancer with spread to the cervical esophagus ; Клинический опыт комбинированного органосохраняющего лечения рака гортаноглотки с распространением на шейный отдел пищевода

Authors: V. A. Rozhnov, P. I. Spirin, V. V. Polkin, I. А. Gulidov, A. V. Dem’yanovich, A. D. Kaprin, S. A. Ivanov, В. А. Рожнов, П. И. Спирин, В. В. Полькин, И. А. Гулидов, А. В. Демьянович, А. Д. Каприн, С. А. Иванов

Source: Head and Neck Tumors (HNT); Том 13, № 3 (2023); 82-88 ; Опухоли головы и шеи; Том 13, № 3 (2023); 82-88 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2023-13-3

Subject Terms: хирургическое лечение, organ-preserving treatment, surgical treatment, органосохраняющее лечение

File Description: application/pdf

Relation: https://ogsh.abvpress.ru/jour/article/view/917/598; Клинические рекомендации Минздрава России по лечению рака гортаноглотки, 2020. Доступно по: https://cr.minzdrav.gov.ru/recomend/27_1.; Пачес А.И. Опухоли головы и шеи. М., Практическая медицина, 2013.; Гордон К.Б., Гулидов И.А., Семенов А.В. и др. Ранние результаты лучевой терапии местно-распространенного рака органов головы и шеи в режиме ускоренного фракционирования. Радиация и риск 2018;27(2):107–16.; Гордон К.Б., Гулидов И.А., Рожнов В.А., Семенов А.В. Возможности химиолучевого лечения первичных местно-распространенных опухолей органов головы и шеи. Онкология. Журнал им. П.А. Герцена 2018;3:68–74.; Cachin Y., Brugere J., Tran-Ba-Huy P., Eschwege F. Results of surgical treatment of cancers of the hypopharynx. Experience at the Institut Gustave-Roussy, Villejuif, 1960–1970. Acta Otorhinolaryngol Belg 1973;27(8):1010–6. (In French).; Рудык А.Н., Сигал Е.И., Насрулаев М.М. и др. Ларингофарингоэзофагэктомия с одномоментной эзофагофаринопластикой в лечении рака шейного отдела пищевода с распространением на гортаноглотку. Поволжский онкологический вестник 2014;2:36–41.; Остринская Т.В., Жуманкулов А.М., Анисимова А.В. Реконструкция постоперационных дефектов при опухолях гортаноглотки и шейного отдела пищевода. Опухоли головы и шеи 2017;7(3):39–46. DOI:10.17650/2222-1468-2017-7-3-39-46; Маджидов М.Г. Новый подход к химиолучевому лечению больных местно-распространенным раком гортаноглотки. Вестник РОНЦ им. Н.Н. Блохина РАМН 2006;17(1):18–9.; Бойков В.П., Гладилина И.А., Павлюк Д.Ю., Струков И.Г. Лечебная тактика при раке гортаноглотки. Практическая онкология 2003;4(1):51–5.; Biau J., Lapeyre M., Idriss Troussier I. et al. Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 Update. Radiother Oncol 2019;134:1–9. DOI:10.1016/j.radonc.2019.01.018; https://ogsh.abvpress.ru/jour/article/view/917

Availability: https://ogsh.abvpress.ru/jour/article/view/917
https://doi.org/10.17650/2222-1468-2023-13-3-82-88

Rationality of sentinel node biopsy in the diagnosis and minimally invasive treatment of patients with breast cancer ; Рациональность биопсии сигнальных лимфатических узлов в диагностике и малоинвазивном лечении пациентов с раком молочной железы

Authors: E. M. Bukin, A. B. Vasin, N. S. Goloshchapova, Э. М. Букин, А. Б. Васин, Н. С. Голощапова

Source: Creative surgery and oncology; Том 12, № 4 (2022); 275-281 ; Креативная хирургия и онкология; Том 12, № 4 (2022); 275-281 ; 2076-3093 ; 2307-0501

Subject Terms: ультрасонография, sentinel lymph node, biopsy, organ-preserving treatment, lymph node removal, magnetic resonance imaging, ultrasonography, сигнальный лимфатический узел, биопсия, органосохраняющее лечение, удаление лимфатического узла, магнитно-резонансная томография

File Description: application/pdf

Relation: https://www.surgonco.ru/jour/article/view/731/517; Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.) Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2021.; Lin A.P., Huang T.W., Tam K.W. Treatment of male breast cancer: meta-analysis of real-world evidence. Br J Surg. 2021;108(9):1034–42. DOI:10.1093/bjs/znab279; Giuliano A.E., Ballman K.V., McCall L., Beitsch P.D., Brennan M.B., Kelemen P.R., et al. Effect of axillary dissection vs no axillary dissection on 10-year overall sur vival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 2017;318(10):918–26. DOI:10.1001/jama.2017.11470; Heiranizadeh N., Rafiei Shahamabadi M., Dehghan H.R., JafariNedooshan J., Kargar S., Zare M., et al. Comparing early-stage breast cancer patients with sentinel lymph node metastasis with and without completion axillary lymph node dissection: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2022;23(8):2561–71. DOI:10.31557/APJCP.2022.23.8.2561; Mathias B.J., Sun J., Sun W., Zhou J.M., Fulp W.J., Laronga C., et al. Surgeon bias in the management of positive sentinel lymph nodes. Clin Breast Cancer. 2021;21(1):74–9. DOI:10.1016/j.clbc.2020.07.010; Семиглазов В.Ф., Криворотько П.В., Жильцова Е.К., Канаев С.В., Труфанова Е.С., Крживицкий П.И. и др. Двадцатилетний опыт изучения биопсии сигнальных лимфатических узлов при раке молочной железы. Опухоли женской репродуктивной системы. 2020;16(1):12–20. DOI:10.17650/1994-4098-2020-16-1-12-20; Ганусевич О.Н., Нестерович Т.Н., Федоркевич И.В. Современные подходы к лечению рака молочной железы (по материалам конференции в Сан-Галлен, 2017). Проблемы здоровья и экологии. 2018;3:12–8. DOI:10.51523/2708-6011.2018-15-3-3; Magnoni F., Galimberti V., Corso G., Intra M., Sacchini V., Veronesi P. Axillary surgery in breast cancer: An updated historical perspective. Semin Oncol. 2020;47(6):341–52. DOI:10.1053/j.seminoncol.2020.09.001; Исмагилов А.Х., Аснина Н.Г., Азаров Г.А. Биопсия сигнальных лимфатических узлов: история и современность. Опухоли женской репродуктивной системы. 2018;14(1):38–46. DOI:10.17650/1994-4098-2018-14-1-38-46; Клинические рекомендации: Рак молочной железы. Министерство здравоохранения Российской Федерации. Кодирование по Международной статистической классификации болезней и проблем, связанных со здоровьем: D05, C50. Год утверждения (частота пересмотра): 2021. Возрастная категория: Взрослые. URL: https://cr.minzdrav.gov.ru/schema/379_4; Винокурова М.А. Независимая оценка качества условий оказания услуг медицинскими организациями: административно-правовые основы регулирования, сущность и значение. Социально-политические науки. 2019;4:125–9.; Кондратова Н.В. Методические подходы к исследованию удовлетворенности пациентов в медицинской организации. В мире научных открытий. 2016;5(77):23–36. DOI:10.12731/wsd-2016-5-2; Kwon B.R., Chang J.M., Lee J., Shin S.U., Lee S.H., Cho N., et al. Detection of axillary lymph node recurrence in patients with personal history of breast cancer treated with sentinel lymph node biopsy (SLNB): results of postoperative combined ultrasound and mammography screening over five consecutive years. Acta Radiol. 2019;60(7):852–8. DOI:10.1177/0284185118805264; Lai H.W., Chang Y.L., Chen S.T., Chang Y.J., Wu W.P., Chen D.R., et al. Revisit the practice of lymph node biopsy in patients diagnosed as ductal carcinoma in situ before operation: a retrospective analysis of 682 cases and evaluation of the role of breast MRI. World J Surg Oncol. 2021;19(1):263. DOI:10.1186/s12957-021-02336-w; Huang X., Shi Z., Mai J., Liu C., Liu C., Chen S., et al. An MRI-based scoring system for preoperative prediction of axillary response to neoadjuvant chemotherapy in node-positive breast cancer: a multicenter retrospective study. Acad Radiol. 2022;S1076-6332(22)00513-X. DOI:10.1016/j.acra.2022.09.022; Di Paola V., Mazzotta G., Pignatelli V., Bufi E., D’Angelo A., Conti M., et al. Staging in breast cancer: importance of MRI and ultrasoundbased imaging. Cancers (Basel). 2022;14(17):4270. DOI:10.3390/cancers14174270; Arisio R., Borella F., Porpiglia M., Durando A., Bellino R., Bau M.G., et al. Axillary dissection vs. no axillary dissection in breast cancer patients with positive sentinel lymph node: a single institution experience. In Vivo. 2019;33(6):1941–7. DOI:10.21873/invivo.11689; Zheng Q., Luo H., Xia W., Lu Q., Jiang K., Hong R., et al. Long-term survival after sentinel lymph node biopsy or axillary lymph node dissection in pN0 breast cancer patients: a population-based study. Breast Cancer Res Treat. 2022 Oct 7. DOI:10.1007/s10549-022-06746-6; Knape N., Park J.H., Agala C.B., Spanheimer P., Morrow M., DownsCanner S., et al. Can we forgo sentinel lymph node biopsy in women aged ≥ 50 years with early-stage hormone-receptor-positive HER2-negative special histologic subtype breast cancer? Ann Surg Oncol. 2022 Oct 10. DOI:10.1245/s10434-022-12626-6; Huo Y., Fan T., Chen S., Liu Q., Fang Y., Yao F. Thematic trends and knowledge structure map of sentinel lymph node biopsy for breast cancer: a bibliometric analysis from 2010 to 2019. Transl Cancer Res. 2022;11(9):3092–107. DOI:10.21037/tcr-21-2841; van Bekkum S., Kraima A.C., Westenend P.J., Plaisier P.W., MenkePluijmers M.B.E. The dilemma after an unforeseen positive sentinel node in primary breast cancer: is completion axillary dissection necessary? World J Surg. 2020;44(11):3801–9. DOI:10.1007/s00268-020-05650-8; https://www.surgonco.ru/jour/article/view/731

Availability: https://www.surgonco.ru/jour/article/view/731
https://doi.org/10.24060/2076-3093-2022-12-4-275-281

POSSIBILITIES OF CONSERVATIVE AND MINIMALLY INVASIVE TREATMENT OF BLUNT INJURY TO PARENCHYMAL ABDOMINAL ORGANS IN ADULTS ; ВОЗМОЖНОСТИ КОНСЕРВАТИВНОГО И МИНИМАЛЬНО ИНВАЗИВНОГО ЛЕЧЕНИЯ ЗАКРЫТЫХ ПОВРЕЖДЕНИЙ ПАРЕНХИМАТОЗНЫХ ОРГАНОВ ЖИВОТА У ВЗРОСЛЫХ

Authors: Мануковский, В.А., Гаврищук, Я.В., Тулупов, А.Н., Демко, А.Е., Савелло, В.Е., Кандыба, Д.В., Колчанов, Е.А.

Source: POLYTRAUMA; № 3 (2022): сентябрь; 21-33 ; ПОЛИТРАВМА / POLYTRAUMA; № 3 (2022): сентябрь; 21-33 ; 2541-867X ; 1819-1495

Subject Terms: blunt abdominal trauma, solid organs injury, selective angioembolization, non-operative management, organ-preserving treatment, закрытая травма живота, повреждение паренхиматозных органов, селективная ангиоэмболизация, неоперативное лечение повреждений паренхиматозных органов, органосохраняющее лечение

File Description: application/pdf

Relation: http://poly-trauma.ru/index.php/pt/article/view/411/692

Availability: http://poly-trauma.ru/index.php/pt/article/view/411

Guideline on trimodal therapy of bladder cancer (Nevskiy consensus 2021) ; Рекомендации по проведению тримодальной терапии рака мочевого пузыря (Невский консенсус 2021)

Authors: R. V. Novikov, S. N. Novikov, A. I. Novikov, S. B. Petrov, S. A. Protsenko, V. V. Protoshchak, S. V. Popov, M. I. Shkolnik, E. S. Shpilenya, A. V. Kurenkov, V. P. Sokurenko, R. V. Orlova, А. K. Nosov, V. D. Korol, D. Kh. Latipova, Yu. V. Mikheeva, S. V. Kanaev, Р. В. Новиков, С. Н. Новиков, А. И. Новиков, С. Б. Петров, С. А. Проценко, В. В. Протощак, С. В. Попов, М. И. Школьник, Е. С. Шпиленя, А. В. Куренков, В. П. Сокуренко, Р. В. Орлова, А. К. Носов, В. Д. Король, Д. Х. Латипова, Ю. В. Михеева, С. В. Канаев

Source: Cancer Urology; Том 18, № 2 (2022); 142-163 ; Онкоурология; Том 18, № 2 (2022); 142-163 ; 1996-1812 ; 1726-9776

Subject Terms: химиотерапия, bladder cancer, muscle-invasive bladder cancer, trimodal therapy, organ-sparing treatment, transurethral resection, radiotherapy, chemotherapy, рак мочевого пузыря, мышечно-инвазивный рак мочевого пузыря, тримодальная терапия, органосохраняющее лечение, трансуретральная резекция, лучевая терапия

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1534/1375; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1087; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1088; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1089; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1090; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1091; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1092; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1534/1093; Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 252 с.; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70(1):7–30. DOI:10.3322/caac.21590; Cumberbatch M.G.K., Jubber I., Black P.C. et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol 2018;74(6):784–95. DOI:10.1016/j.eururo.2018.09.001; Rodrigues Pessoa R., Mueller A.C., Boxley P. et al. Systematic review and meta‑analysis of radiation therapy for high‑risk non‑muscle invasive bladder cancer. Urol Oncol 2021;39(11):786.e1–8. DOI:10.1016/j.urolonc.2021.03.009; Witjes J.A., Bruins H.M., Cathomas R. et al. European Association of Urology guidelines on muscle‑invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 2021;79(1):82–104. DOI:10.1016/j.eururo.2020.03.055; Chang S.S., Bochner B.H., Chou R. et al. Treatment of non‑metastatic muscle‑invasive bladder cancer: AUA/ASCO/ASTRO/ SUO Guideline. J Urol 2017;198(3):552–9. DOI:10.1016/j.juro.2017.04.086; Flaig T.W., Spiess P.E., Agarwal N. et al. Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020;18(3):329–54. DOI:10.6004/jnccn.2020.0011; Witjes J.A., Babjuk M., Bellmunt J. et al. EAU‑ESMO consensus statements on the management of advanced and variant bladder cancer – an international collaborative multistakeholder effort: under the auspices of the EAU‑ESMO guidelines committees. Eur Urol 2020;77(2):223–50. DOI:10.1016/j.eururo.2019.09.035; Choi H., Park J.Y., Bae J.H., Tae B.S. Health‑related quality of life after radical cystectomy. Transl Androl Urol 2020;9(6):2997–3006. DOI:10.21037/tau.2020.02.01; Hautmann R.E., de Petriconi R.C., Volkmer В.G. Lessons learned from 1,000 neobladders: the 90‑day complication rate. J Urol 2010;184(3):990–4. DOI:10.1016/j.juro.2010.05.037; Nielsen M.E., Mallin K., Weaver M.A. et al. Association of hospital volume with conditional 90‑day mortality after cystectomy: an analysis of the National Cancer Data Base. BJU Int 2014;114(1):46–55. DOI:10.1111/bju.12566; Maffezzini M., Fontana V., Pacchetti A. et al. Age above 70 years and Charlson Comorbidity Index higher than 3 are associated with reduced survival probabilities after radical cystectomy for bladder cancer. Data from a contemporary series of 334 consecutive patients. Arch Ital Urol Androl 2021;93(1):15–20. DOI:10.4081/aiua.2021.1.15; Novotny V., Froehner M., Koch R. et al. Age, American Society of Anesthesiologists physical status classification and Charlson score are independent predictors of 90‑day mortality after radical cystectomy. World J Urol 2016;34(8):1123–9. DOI:10.1007/s00345‑015‑1744‑8; Howlader N., Noone A.M., Krapcho M. et al. (2017) SEER cancer statistics review, 1975–2014. National Cancer Institute, Bethesda, MD. Available at: https://seer.cancer.gov/csr/1975_2014.; Kimura T., Ishikawa H., Kojima T. et al. Bladder preservation therapy for muscle invasive bladder cancer: the past, present and future. Jpn J Clin Oncol 2020;50(10):1097–107. DOI:10.1093/jjco/hyaa155; Varughese M., Treece S., Drinkwater K.J. Radiotherapy management of muscle invasive bladder cancer: evaluation of a national cohort. Clin Oncol (R Coll Radiol) 2019;31(9):637–45. DOI:10.1016/j.clon.2019.04.009; Giacalone N.J., Shipley W.U., Clayman R.H. et al. Long‑term outcomes after bladderpreserving tri‑modality therapy for patients with muscle‑invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience. Eur Urol 2017;71(6):952–60. DOI:10.1016/j.eururo.2016.12.020; Francolini G., Borghesi S., Fersino S. et al. Treatment of muscle‑invasive bladder cancer in patients without comorbidities and fit for surgery: trimodality therapy vs radical cystectomy. Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Crit Rev Oncol Hematol 2021;159:103235. DOI:10.1016/j.critrevonc.2021.103235; Kulkarni G.S., Hermanns T., Wei Y. et al. Propensity score analysis of radical cystectomy versus bladder‑sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol 2017;35(20):2299–305. DOI:10.1200/JCO.2016.69.2327; Ding H., Fan N., Ning Z., Ma D. Trimodal therapy vs. radical cystectomy for muscleinvasive bladder cancer: a meta‑analysis. Front Oncol 2020;10:564779. DOI:10.3389/fonc.2020.564779; Deuker M., Krimphove M.J., Stolzenbach L.F. et al. Radical cystectomy vs. multimodality treatment in T2N0M0 bladder cancer: a population‑based, agematched analysis. Clin Genitourin Cancer 2021;19(4):e264–71. DOI:10.1016/j.clgc.2021.03.010; Pieretti A., Krasnow R., Drumm M. et al. Complications and outcomes of salvage cystectomy after trimodality therapy. J Urol 2021;206(1):29–36. DOI:10.1097/JU.0000000000001696; Клинические рекомендации. Рак мочевого пузыря. Министерство здравоохранения Российской Федерации, 2020. Доступно по: https://cr.minzdrav.gov.ru.; Pieters B.R., van der Steen‑Banasik E., Smits G.A. et al. GEC‑ESTRO/ACROP recommendations for performing bladdersparing treatment with brachytherapy for muscle‑invasive bladder carcinoma. Radiother Oncol 2017;122(3):340–6. DOI:10.1016/j.radonc.2016.12.022; Der Steen‑Banasik E.V., Oosterveld B., Smits G. et al. Perpetual role of brachytherapy in organ‑sparing treatment for bladder cancer: a historical review. J Contemp Brachytherapy 2020;12(6): 618–28. DOI:10.5114/jcb.2020.101697; Heidegger I., Oberaigner W., Horninger W., Pichler R. High incidence of clinically significant concomitant prostate cancer in patients undergoing radical cystectomy for bladder cancer: a 10‑year single‑center experience. Urol Oncol 2017;35(4):152.e1–5. DOI:10.1016/j.urolonc.2016.11.004; Kumar A., Cherry D.R., Courtney P.T. et al. Outcomes for muscle‑invasive bladder cancer with radical cystectomy or trimodal therapy in US veterans. Eur Urol Open Sci 2021;30:1–10. DOI:10.1016/j.euros.2021.05.009; Zhu Z., Zhao J., Li Y. et al. Prognostic value of preoperative hydronephrosis in patients with bladder cancer undergoing radical cystectomy: a meta‑analysis. PLoS One 2019;14(9):e0222223. DOI:10.1371/journal.pone.0222223; Krasnow R.E., Drumm M., Roberts H.J. et al. Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder‑sparing therapy. Eur Urol 2017;72(1):54–60. DOI:10.1016/j.eururo.2016.12.002; Bertz S., Wach S., Taubert H. et al. Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy. Virchows Arch 2016;469(3):339–44. DOI:10.1007/s00428‑016‑1986‑x; Nagumo Y., Kojima T., Shiga M. et al. A single‑institute experience of trimodal bladder‑preserving therapy for histologic variants of urothelial carcinoma. Int J Clin Oncol 2020;25(2):354–61. DOI:10.1007/s10147‑019‑01553‑4; Khalifa J., Supiot S., Pignot G. et al. Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder. Radiother Oncol 2021;161:95–114. DOI:10.1016/j.radonc.2021.06.011; Premo C., Apolo A.B., Agarwal P.K., Citrin D.E. Trimodality therapy in bladder cancer: who, what, and when? Urol Clin North Am 2015;42(2):169–80. DOI:10.1016/j.ucl.2015.02.002; Hindson B.R., Turner S.L., Millar J.L. et al. RANZCR Faculty of Radiation Oncology Genito‑Urinary Group (FROGG). Australian & New Zealand Faculty of Radia‑tion Oncology Genito‑Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder. J Med Imaging Radiat Oncol 2012;56(1):18–30. DOI:10.1111/j.1754‑9485.2011.02336.x; Gofrit O.N., Meirovitz A., Frank S. et al. Trimodal therapy in T2–4aN0M0 bladder cancer – how to select the best candidate? Cancer Med 2020;9(22):8491–7. DOI:10.1002/cam4.3478; Huddart R.A., Birtle A., Maynard L. et al. Clinical and patient‑reported outcomes of SPARE – a randomised feasibility study of selective bladder preservation versus radical cystectomy. BJU Int 2017; 120(5): 639–50. DOI:10.1111/bju.13900; Freeman R.M. How urgent is urgency? A review of current methods of assessment. Int Urogynecol J Pelvic Floor Dysfunct 2005;16(2):93–5. DOI:10.1007/s00192‑004‑1253‑6; Feldman A.S., Kulkarni G.S., Bivalacqua T.J. et al. Surgical challenges and considerations in tri‑modal therapy for muscle invasive bladder cancer. Urol Oncol 2021:S1078–1439(21)00012–0. DOI:10.1016/j.urolonc.2021.01.013; Nguyen E.K., Yu H., Pond G. et al. Outcomes of trimodality bladder‑sparing therapy for muscle‑invasive bladder cancer. Can Urol Assoc J 2020;14(4):122–9. DOI:10.5489/cuaj.5945; Russell C.M., Lebastchi A.H., Borza T. et al. The Role of transurethral resection in trimodal therapy for muscle‑invasive bladder cancer. Bladder Cancer 2016;2(4):381–94. DOI:10.3233/BLC‑160076; Ouzaid I., Panthier F., Hermieu J.F., Xylinas E. Contemporary surgical and technical aspects of transurethral resection of bladder tumor. Transl Androl Urol 2019;8(1):21–4. DOI:10.21037/tau.2019.01.04; Russo G.I., Sholklapper T.N., Cocci A. et al. Performance of narrow band imaging (NBI) and photodynamic diagnosis (PDD) fluorescence imaging compared to white light cystoscopy (WLC) in detecting non‑muscle invasive bladder cancer: a systematic review and lesion‑level diagnostic meta‑analysis. Cancers (Basel) 2021;13(17):4378. DOI:10.3390/cancers13174378; Babjuk M., Burger M., Capoun O. et al. European Association of Urology guidelines on non‑muscle‑invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 2021;81(1):75–94. DOI:10.1016/j.eururo.2021.08.010; Новиков А.И., Леоненков Р.В., Темкин Д.Б. и др. Трансуретральная резекция карциномы мочевого пузыря, распространяющейся на устье мочеточника. Онкоурология 2021;17(2):104–11. DOI:10.17650/1726‑9776‑2021‑17‑2104‑111; Hafeez S., Lewis R., Hall E., Huddart R. RAIDER trial management group. Advancing radiotherapy for bladder cancer: randomised phase II trial of adaptive image‑guided standard or dose‑escalated tumour boost radiotherapy (RAIDER). Clin Oncol (R Coll Radiol) 2021;33(6):e251–6. DOI:10.1016/j.clon.2021.02.012; Nolan C.P., Forde E.J. A review of the use of fiducial markers for image‑guided bladder radiotherapy. Acta Oncol 2016;55(5):533–8. DOI:10.3109/0284186X.2015.1110250; De Ridder M., Gerbrandy L.C., de Reijke T.M. et al. BioXmark® liquid fiducial markers for image‑guided radiotherapy in muscle invasive bladder cancer: a safety and performance trial. Br J Radiol 2020;93(1111):20200241. DOI:10.1259/bjr.20200241; Russell B., Liedberg F., Khan М.S. et al. Systematic review and meta‑analysis of delay in radical cystectomy and the effect on survival in bladder cancer patients. Eur Urol Oncol 2020;3(2):239–49. DOI:10.1016/j.euo.2019.09.008; Yin M., Joshi M., Meijer R.P. et al. Chemotherapy for muscle‑invasive bladder cancer: a systematic review and two‑step meta‑analysis. Oncologist 2016;21(6):708–15. DOI:10.1634/theoncologist.2015‑0440; Vale C.L. Advanced Bladder Cancer (ABC) Meta‑analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and metaanalysis of individual patient data advanced bladder cancer (ABC) meta‑analysis collaboration. Eur Urol 2005;48(2):202–6; discussion 205–6. DOI:10.1016/j.eururo.2005.04.006; Griffiths G., Hall R., Sylvester R. et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscleinvasive bladder cancer: long‑term results of the BA06 30894 trial. J Clin Oncol 2011;29(16):2171–7. DOI:10.1200/JCO.2010.32.3139; Kragelj B., Zaletel‑Kragelj L., Sedmak B. et al. Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. Radiother Oncol 2005;75(1):44–7. DOI:10.1016/j.radonc.2005.01.007; Tester W., Caplan R., Heaney J. et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996;14(1):119–26. DOI:10.1200/JCO.1996.14.1.119; Lin C.C., Hsu C.H., Cheng J.C. et al. Induction cisplatin and fluorouracil‑based chemotherapy followed by concurrent chemoradiation for muscle‑invasive blad‑der cancer. Int J Radiat Oncol Biol Phys 2009;75(2):442–8. DOI:10.1016/j.ijrobp.2008.11.030; Smith Z.L., Christodouleas J.P., Keefe S.M. et al. Bladder preservation in the treatment of muscle‑invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int 2013;112(1):13–25. DOI:10.1111/j.1464‑410X.2012.11762.x; Efstathiou J.A., Spiegel D.Y., Shipley W.U. et al. Long‑term outcomes of selective bladder preservation by combined‑modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61(4):705–11. DOI:10.1016/j.eururo.2011.11.010; Ajib K., Tjong M.C., Tan G.H. et al. Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle‑invasive bladder cancer. Can Urol Assoc J 2020;14(12):404–10. DOI:10.5489/cuaj.6459; Royce T.J., Liu Y., Milowsky M.I. et al. Trimodality therapy with or without neoadjuvant chemotherapy for muscle‑invasive bladder cancer. Clin Genitourin Cancer 2021;19(4):362–8. DOI:10.1016/j.clgc.2021.03.007; Mitin T., Dengina N., Chernykh M. et al. Management of muscle invasive bladder cancer with bladder preservation in Russia: a survey‑based analysis of current practice and the impact of an educational workshop on clinical expertise. J Cancer Educ 2021;36(5):1005–13. DOI:10.1007/s13187‑020‑01728‑y; Cowan R.A., McBain C.A., Ryder W.D. et al. Radiotherapy for muscle‑invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose‑escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys 2004;59(1):197–207. DOI:10.1016/j.ijrobp.2003.10.018; Huddart R.A., Hall E., Hussain S.A. et al. Randomized noninferiority trial of reduced high‑dose volume versus standard volume radiation therapy for muscle‑invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int J Radiat Oncol Biol Phys 2013;87(2):261–9. DOI:10.1016/j.ijrobp.2013.06.2044; Nixon R.G., Chang S.S., Lafleur B.J. et al. Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J Urol 2002;167(2 Pt 1):502–5. DOI:10.1097/00005392‑200202000‑00012; Kefer J.C., Voelzke B.B., Flanigan R.C. et al. Risk assessment for occult malignancy in the prostate before radical cystectomy. Urology 2005;66(6):1251–5. DOI:10.1016/j.urology.2005.07.006; Stein J.P., Penson D.F., Wu S.D., Skinner D.G. Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the litera‑ture. J Urol 2007;178(3 Pt 1):756–60. DOI:10.1016/j.juro.2007.05.013; Rödel C., Grabenbauer G.G., Kühn R. et al. Combined‑modality treatment and selective organ preservation in invasive bladder cancer: long‑term results. J Clin Oncol 2002;20(14):3061–71. DOI:10.1200/JCO.2002.11.027; Arcangeli G., Arcangeli S., Strigari L. A systematic review and meta‑analysis of clinical trials of bladder‑sparing trimodality treatment for muscle‑invasive bladder cancer (MIBC). Crit Rev Oncol Hematol 2015;94(1):105–15. DOI:10.1016/j.critrevonc.2014.11.007; Van Leeuwen C.M., Oei A.L., Crezee J. et al. The alfa and beta of tumours: a review of parameters of the linear‑quadratic model, derived from clinical radiotherapy studies. Radiat Oncol 2018;13(1):96. DOI:10.1186/s13014‑018‑1040‑z; Hoskin P.J., Rojas A.M., Bentzen S.M., Saunders M.I. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010;28(33):4912–8. DOI:10.1200/JCO.2010.28.4950; James N.D., Hussain S.A., Hall E. et al. Radiotherapy with or without chemotherapy in muscle‑invasive bladder cancer. N Engl J Med 2012;366(16):1477–88. DOI:10.1056/NEJMoa1106106; Choudhury A., Swindell R., Logue J.P. et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle‑invasive bladder cancer. J Clin Oncol 2011;29(6):733–8. DOI:10.1200/JCO.2010.31.5721; Thompson C., Joseph N., Sanderson B. et al. Tolerability of concurrent chemoradiation therapy with gemcitabine (GemX), with and without prior neoadjuvant chemotherapy, in muscle invasive bladder cancer. Int J Radiat Oncol Biol Phys 2017;97(4):732–9. DOI:10.1016/j.ijrobp.2016.11.040; Hussain S.A., Stocken D.D., Peake D.R. et al. Long‑term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer 2004;90(11):2106–11. DOI:10.1038/sj.bjc.6601852; Choudhury A., Porta N., Hall E. et al. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta‑analysis of the BC2001 and BCON trials. Lancet Oncol 2021;22(2):246–55. DOI:10.1016/S1470‑2045(20)30607‑0; Zietman A.L., Grocela J., Zehr E. et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 2001;58(3):380–5. DOI:10.1016/s0090‑4295(01)01219‑5; Pos F.J., Hart G., Schneider C., Sminia P. Radical radiotherapy for invasive bladder cancer: what dose and fractionation schedule to choose? Int J Radiat Oncol Biol Phys 2006;64(4):1168–73. DOI:10.1016/j.ijrobp.2005.09.023; Whalley D., Caine H., McCloud P. et al. Promising results with image guided intensity modulated radiotherapy for muscle invasive bladder cancer. Radiat Oncol 2015;10:205. DOI:10.1186/s13014‑015‑0499‑0; Murthy V., Gupta P., Baruah K. et al. Adaptive radiotherapy for carcinoma of the urinary bladder: long‑term outcomes with dose escalation. Clin Oncol (R Coll Radiol) 2019;31(9):646–52. DOI:10.1016/j.clon.2019.06.005; Hafeez S., Warren‑Oseni K., McNair H.A. et al. Prospective study delivering simultaneous integrated high‑dose tumor boost (≤70 Gy) with image guided adaptive radiation therapy for radical treatment of localized muscle‑invasive bladder cancer. Int J Radiat Oncol Biol Phys 2016;94(5):1022–30. DOI:10.1016/j.ijrobp.2015.12.379; Kibrom A.Z., Knight K.A. Adaptive radiation therapy for bladder cancer: a review of adaptive techniques used in clinical practice. J Med Radiat Sci 2015;62(4):277–85. DOI:10.1002/jmrs.129; Stein J.P., Lieskovsky G., Cote R. et al. Radical cystectomy in the treatment of invasive bladder cancer: long‑term results in 1,054 patients. J Clin Oncol 2001;19(3):666–75. DOI:10.1200/JCO.2001.19.3.666; Tunio M.A., Hashmi A., Qayyum A. et al. Whole‑pelvis or bladder‑only chemoradiation for lymph node‑negative invasive bladder cancer: single‑institution experience. Int J Radiat Oncol Biol Phys 2012;82(3):e457–62. DOI:10.1016/j.ijrobp.2011.05.051; Mari A., Kimura S., Foerster B. et al. A systematic review and meta‑analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. BJU Int 2019;123(1):11–21. DOI:10.1111/bju.14417; Werntz R.P., Smith Z.L., Packiam V.T. et al. The impact of lymphovascular invasion on risk of upstaging and lymph node metastasis at the time of radical cystectomy. Eur Urol Focus 2020;6(2):292–7. DOI:10.1016/j.euf.2018.09.019; Goldsmith B., Baumann B.C., He J. et al. Occult pelvic lymph node involvement in bladder cancer: implications for definitive radiation. Int J Radiat Oncol Biol Phys 2014;88(3):603–10. DOI:10.1016/j.ijrobp.2013.11.211; Hall E., Hussain S.A., Porta N. et al. BC2001 long‑term outcomes: a phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high‑dose volume RT in muscle‑invasive bladder cancer. J Clin Oncol 2017;35:280. DOI:10.1200/JCO.2017.35.6_suppl.280; Джойнер М.С., ван дер Когель О.Д. Основы клинической радиобиологии. Гл. 18. Совместное применение лучевой и химиотерапии. Пер. с англ. М.: БИНОМ. Лаборатория знаний, 2013. 600 с.; Coen J.J., Zhang P., Saylor P.J. et al. Bladder preservation with twice‑a‑day radiation plus fluorouracil/cisplatin or once daily radiation plus gemcitabine for muscle‑invasive bladder cancer: NRG/RTOG 0712 – а randomized phase II trial. J Clin Oncol 2019;37(1):44–51. DOI:10.1200/JCO.18.00537; Гладков О. А., Зуков Р.А., Матвеев В. Б. и др. Практические рекомендации по лекарственному лечению рака мочевого пузыря. Злокачественные опухоли: Практические рекомендации RUSSCO 2021;11(32). DOI:10.18027/2224‑5057‑2021‑11‑3s2‑32; Portner R., Bajaj A., Elumalai T. et al. A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle‑invasive bladder cancer. Clin Transl Radiat Oncol 2021;31:1–7. DOI:10.1016/j.ctro.2021.08.003; Caffo O., Thompson C., De Santis M. et al. Concurrent gemcitabine and radiotherapy for the treatment of muscle‑invasive bladder cancer: a pooled individual data analysis of eight phase I–II trials. Radiother Oncol 2016;121(2):193–8. DOI:10.1016/j.radonc.2016.09.006; Wettstein M.S., Rooprai J.K., Pazhepurackel C. et al. Systematic review and meta‑analysis on trimodal therapy versus radical cystectomy for muscleinvasive bladder cancer: does the current quality of evidence justify definitive conclusions? PLoS One 2019;14(4):e0216255. DOI:10.1371/journal.pone.0216255; Mak R.H., Hunt D., Shipley W.U. et al. Long‑term outcomes in patients with muscleinvasive bladder cancer after selective bladder‑preserving combined‑modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 2014;32(34):3801–9. DOI:10.1200/JCO.2014.57.5548; Bladder cancer: diagnosis and management of bladder cancer: ©NICE (2015) Bladder cancer: diagnosis and management of bladder cancer. BJU Int 2017;120(6):755–65. DOI:10.1111/bju.14045; Payne H., Adamson A., Bahl A. et al. Chemicaland radiation‑induced haemorrhagic cystitis: current treatments and challenges. BJU Int 2013;112(7):885– 97. DOI:10.1111/bju.12291; Kool R., Marcq G., El‑Achkar A. et al. Refining assessment of response to radiation‑based therapy for muscleinvasive bladder cancer: is post‑treatment tumor bed biopsy always necessary? Urol Oncol 2021;39(5):299.e7–14. DOI:10.1016/j.urolonc.2020.10.001; Spencer K., Jones C.M., Girdler R. et al. The impact of the COVID‑19 pandemic on radiotherapy services in England UK: a population‑based study. Lancet Oncol 2021;22(3):309–20. DOI:10.1016/S1470‑2045(20)30743‑9; Mitin T., Choudhury A. The role of biomarkers in bladder preservation management of muscle‑invasive bladder cancer. World J Urol 2019;37(9):1767–72. DOI:10.1007/s00345‑018‑2480‑7; Wu C.T., Chen W.C., Chang Y.H. et al. The role of PD‑L1 in the radiation response and clinical outcome for bladder cancer. Sci Rep 2016;6:19740. DOI:10.1038/srep19740; https://oncourology.abvpress.ru/oncur/article/view/1534

Availability: https://oncourology.abvpress.ru/oncur/article/view/1534
https://doi.org/10.17650/1726-9776-2022-18-2-142-163

Bladder leiomyosarcoma originating from the muscular elements of the bladder mucosa (clinical case) ; Лейомиосаркома мочевого пузыря, исходящая из мышечных элементов слизистой оболочки мочевого пузыря (клинический случай)

Authors: I. A. Reva, K. M. Nyushko, E. N. Plekhanova, V. D. Sanikovich, A. S. Chernushenko, N. D. Akhvlediani, D. Yu. Pushkar, И. А. Рева, К. М. Нюшко, Е. Н. Плеханова, В. Д. Саникович, А. С. Чернушенко, Н. Д. Ахвледиани, Д. Ю. Пушкарь

Source: Cancer Urology; Том 18, № 1 (2022); 106-111 ; Онкоурология; Том 18, № 1 (2022); 106-111 ; 1996-1812 ; 1726-9776

Subject Terms: активное наблюдение, bladder, organ-preserving treatment, transurethral resection, active surveillance, мочевой пузырь, органосохраняющее лечение, трансуретральная резекция

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1512/1355; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1512/1068; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1512/1069; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1512/1070; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1512/1071; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1512/1072; Labanaris A.P., Zugor V., Meyer B. et al. Urinary bladder leiomyosarcoma in adults. Int Urol Nephrol 2008;40(2):311–6. DOI:10.1007/s11255-007-9288-5.; Menon A.R., Puthalath R.T., Suresh N., Hegde S. Organ preservation in leiomyosarcoma bladder: case report and review of literature. Urol Ann 2018;10(2):233–6. DOI:10.4103/UA.UA_109_17.; Baurys W., Landes R.R. Leiomyosarcoma of the bladder; report of a case. Guthrie Clin Bull 1946;15:127–32.; Zieschang H., Koch R., Wirth M.P., Froehner M. Leiomyosarcoma of the urinary bladder in adult patients: a systematic review of the literature and meta-analysis. Urol Int 2019;102(1):96–101. DOI:10.1159/000494357.; Coiner B.L., Cates J., Kamanda S. et al. Leiomyosarcoma of the urinary bladder: a SEER database study and comparison to leiomyosarcomas of the uterus and extremities/trunk. Ann Diagn Pathol 2021;53:151743. DOI:10.1016/j.anndiagpath.2021.151743.; Rodríguez D., Preston M.A., Barrisford G.W. et al. Clinical features of leiomyosarcoma of the urinary bladder: analysis of 183 cases. Urol Oncol 2014;32(7):958–65. DOI:10.1016/j.urolonc.2014.01.025.; Parekh D.J., Jung C., O’Conner J. et al. Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblas­toma and review of bladder sarcomas. Urology 2002;60(1):164. DOI:10.1016/s0090-4295(02)01701-6.; Brucker B., Ernst L., Meadows A., Zderic S. A second leiomyosarcoma in the urinary bladder of a child with a history of retinoblastoma 12 years following partial cystectomy. Pediatr Blood Cancer 2006;46(7):811–4. DOI:10.1002/pbc.20506.; Ramírez Sevilla C., Admella-Salvador C., Romero-Martin J.A. et al. Bladder leiomyosarcoma 25 years after treatment with cyclophosphamide in patient with history of retinoblastoma. Urol Int 2018;100(1): 119–21. DOI:10.1159/000437442.; Tanguay C., Harvey I., Houde M. et al. Leiomyosarcoma of urinary bladder following cyclophosphamide therapy: report of two cases. Mod Pathol 2003;16(5):512–4. DOI:10.1097/01.MP.0000068237.38715.D9.; Онкологическая база данных My Cancer Genome. Доступно по: https://www.mycancergenome.org/content/disease/leiomyosarcoma/.; Rosser C.J., Slaton J.W., Izawa J.I. et al. Clinical presentation and outcome of highgrade urinary bladder leiomyosarcoma in adults. Urology 2003;61(6):1151–5. DOI:10.1016/s0090-4295(03)00021-9.; Hamadalla N.Y., Rifat U.N., Safi K.C. et al. Leiomyosarcoma of the urinary bladder: a review and a report of two further cases. Arab J Urol 2013;11(2):159–64. DOI:10.1016/j.aju.2013.03.004.; Slaoui H., Sanchez-Salas R., Validire P. et al. Urinary bladder leiomyosarcoma: primary surgical treatment. Urol Case Rep 2014;2(4):137–8. DOI:10.1016/j.eucr.2014.05.002.; https://oncourology.abvpress.ru/oncur/article/view/1512

Availability: https://oncourology.abvpress.ru/oncur/article/view/1512
https://doi.org/10.17650/1726-9776-2022-18-1-106-111

Comparison of perioperative and short-term functional outcomes of laparoscopic partial nephrectomy in patients with cT1aN0M0 and cT1b-T2aN0M0 tumors ; Сравнение периоперационных и ранних функциональных результатов лапароскопической резекции почки с опухолью при стадии cT1aN0M0 и cT1b-T2aN0M0

Authors: S. V. Kotov, A. A. Nemenov, A. G. Yusufov, R. I. Guspanov, S. A. Pulbere, A. O. Prostomolotov, С. В. Котов, А. А. Неменов, А. Г. Юсуфов, Р. И. Гуспанов, С. А. Пульбере, А. О. Простомолотов

Source: Cancer Urology; Том 17, № 4 (2021); 38-46 ; Онкоурология; Том 17, № 4 (2021); 38-46 ; 1996-1812 ; 1726-9776

Subject Terms: органосохраняющее лечение, kidney tumor, laparoscopic partial nephrectomy, nephron-sparing surgery, опухоль почки, лапароскопическая резекция почки

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1470/1326; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1470/1002; Состояние онкологической помощи населению России в 2019 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 239 с.; Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer. Available at: https://gco.iarc.fr/today. (accessed March 2, 2020).; Campbell S., Uzzo R.G., Allaf M.E. et al. Renal mass and localized renal cancer: AUA guideline. J Urol 2017;198(3):520-9. DOI:10.1016/j.juro.2017.04.100.; Lee H., Oh J.J., Byun S.S. et al. Can partial nephrectomy provide equal oncological efficiency and safety compared with radical nephrectomy in patients with renal cell carcinoma (≥4 cm)? A propensity score-matched study. Urol Oncol 2017;35(6):379-85. DOI:10.1016/j.urolonc.2017.02.002.; SEER Explorer. Available at: https://seer.cancer.gov/explorer/index.html. (accessed March 2, 2020).; Chevrier S., Levine J.H., Zanotelli V.R.T. et al. An immune atlas of clear cell renal cell carcinoma. Cell 2017;169(4):736-49.e718. DOI:10.1016/j.cell.2017.04.016.; Kane C.J., Mallin K., Ritchey J. et al. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer 2008;113(1):78-83. DOI:10.1002/cncr.23518.; Campbell S.C., Novick A.C., Belldegrun A. et al. Guideline for management of the clinical T1 renal mass. J Urol 2009;182(4):1271-9. DOI:10.1016/j.juro.2009.07.004.; Liss M.A., Wang S., Palazzi K. et al. Evaluation of national trends in the utilization of partial nephrectomy in relation to the publication of the American Urologic Association guidelines for the management of clinical T1 renal masses. BMC Urol 2014;14:101. DOI:10.1186/1471-2490-14-101.; Krane L.S., Hemal A.K. Robotic and laparoscopic partial nephrectomy for T1b tumors. Curr Opin Urol 2013;23(5):418-22. DOI:10.1097/MOU.0b013e32836320d2.; Al-Qudah S., Rodriguez A.R., Sexton W.J. Laparoscopic management of kidney cancer: updated review. Cancer Control 2007;14(3):218-30. DOI:10.1177/107327480701400304.; Van Poppel H., Da Pozzo L., Albrecht W. et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephronsparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011;59(4):543-52. DOI:10.1016/j.eururo.2010.12.013.; Аляев Ю.Г., Сирота Е.С., Рапопорт Л.М. и др. Сравнение значимости шкал нефрометрической оценки RENAL, PADUA, С-index для прогноза сложности лапароскопической резекции почки. Онкоурология 2018;14(1):36-46. DOI:10.17650/1726-97762018-14-1-36-46.; Colombo J.R.Jr, Haber G.P., Gill I.S. Laparoscopic partial nephrectomy in patients with compromised renal function. Urology 2008;71(6):1043-8. DOI:10.1016/j.urology.2007.11.022.; Chan A.A., Wood C.G., Caicedo J. et al. Predictors of unilateral renal function after open and laparoscopic partial nephrectomy. Urology 2010;75(2):295-302. DOI:10.1016/j.urology.2009.09.027.; La Rochelle J., Shuch B., Riggs S. et al. Functional and oncological outcomes of partial nephrectomy of solitary kidneys. J Urol 2009;181(5):2037-42. DOI:10.1016/j.juro.2009.01.024; Berczi C., Thomas B., Bacso Z., Flasko T. Long-term oncological and functional outcomes of partial nephrectomy in solitary kidneys. Clin Genitourin Cancer 2016;14(3):e275-81. DOI:10.1016/j.clgc.2015.11.014.; Alyami F., Rendon R. Laparoscopic partial nephrectomy for >4 cm renal masses. Canad Urol Assoc J 2013;7(5-6):281. DOI:10.5489/cuaj.1003.; Сирота Е.С., Рапопорт Л.М., Гридин В.Н. и др. Анализ кривой обучения хирургов в зависимости от сложности нефрометрической оценки при выполнении лапароскопической резекции почки у пациентов с локализованными образованиями паренхимы почки. Урология 2020;6: 11-8. DOI:10.18565/urology.2020.6.11-18.; Bahler C.D., Sundaram C.P. Effect of renal reconstruction on renal function after partial nephrectomy. J Endourol 2016;30(Suppl 1):S37-41. DOI:10.1089/end.2016.0055.; Tubre R.W., Parker W.P., Dum T. et al. Findings and impact of early imaging after partial nephrectomy. J Endourol 2017;31(3):320-5. DOI:10.1089/end.2016.0568.; Kim T.S., Park J.G., Kang H. et al. Computed tomography imaging features and changes in hemostatic agents after laparoscopic partial nephrectomy. J Endourology 2016;30(9):950-7. DOI:10.1089/end.2016.0263.; Novick A.C., Streem S., Montie J.E. et al. Conservative surgery for renal cell carcinoma: a single-center experience with 100 patients. J Urol 1989;141(4):835-9. DOI:10.1016/s0022-5347(17)41026-3.; Lapini A., Serni S., Minervini А. et al. Progression and long-term survival after simple enucleation for the elective treat- mentof renal cell carcinoma: experience in 107 patients. J Urol 2005;174(1):57-60. DOI:10.1097/01.ju.0000162019.45820.53.; Serni S., Vittori G., Frizzi J. et al. Simple enucleation for the treatment of highly complex renal tumors: perioperative, functional and oncological results. Eur J Surg Oncol 2015;41(7):934-40. DOI:10.1016/j.ejso.2015.02.019.; Wood E.L., Adibi M., Qiao W. et al. Local tumor bed recurrence following partial nephrectomy in patients with small renal masses. J Urol 2018;199(2):393-400. DOI:10.1016/j.juro.2017.09.072; Аляев Ю.Г., Рапопорт Л.М., Сирота Е.С. и др. Местный рецидив после выполнения лапароскопических резекций при раке паренхимы почки. Андрология и генитальная хирургия 2017;18(4):61-8. DOI:10.17650/2070-9781-2017-18-4-61-68.; Волкова М.И., Ридин В.А., Черняев В.А. и др. Нужна ли технически сложная резекция больным опухолями почечной паренхимы с нормальной контралатеральной почкой? Онкоурология 2019;15(4):39-49. DOI:10.17650/1726-97762019-15-4-39-49.; https://oncourology.abvpress.ru/oncur/article/view/1470

Availability: https://oncourology.abvpress.ru/oncur/article/view/1470
https://doi.org/10.17650/1726-9776-2021-17-4-38-46

Minimally Invasive Treatment of Benign Thyroid Nodules

Authors: G. T. Gumerova, G. M. Gubaidullina, F. R. Nagaev, R. R. Bakiev, N. S. Suleymanova

Source: Креативная хирургия и онкология, Vol 12, Iss 1, Pp 43-47 (2022)

Subject Terms: щитовидной железы болезни, доброкачественный узел щитовидной железы, узловой зоб, радиочастотная абляция, склеротерапия, органосохраняющее лечение, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Relation: https://www.surgonco.ru/jour/article/view/673; https://doaj.org/toc/2307-0501; https://doaj.org/toc/2076-3093; https://doaj.org/article/bbc9452c830041a09e034aaef380eb0e

Availability: https://doi.org/10.24060/2076-3093-2022-12-1-43-47
https://doaj.org/article/bbc9452c830041a09e034aaef380eb0e

Clinical Experience with Organ-Preserving Surgery in Placenta Accreta

Authors: A. G. Arutyunyants, M. B. Ovchinnikova

Source: Креативная хирургия и онкология, Vol 12, Iss 3, Pp 230-236 (2022)

Subject Terms: плацента, врастание плаценты, кесарево сечение, рубец на матке, метропластика, органосохраняющее лечение, временный интраоперационный гемостаз, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Relation: https://www.surgonco.ru/jour/article/view/719; https://doaj.org/toc/2307-0501; https://doaj.org/toc/2076-3093; https://doaj.org/article/c7a0a1c14f6346138e16a9068313a6e8

Availability: https://doi.org/10.24060/2076-3093-2022-12-3-230-236
https://doaj.org/article/c7a0a1c14f6346138e16a9068313a6e8

ANALYSIS OF METASTASIS-FREE SURVIVAL IN PATIENTS WITH SMALL CHOROID MELANOMA DEPENDING ON THE TYPE OF PRIMARY TUMOR TREATMENT ; АНАЛИЗ БЕЗМЕТАСТАТИЧЕСКОЙ ВЫЖИВАЕМОСТИ ПАЦИЕНТОВ С МЕЛАНОМОЙ ХОРИОИДЕИ МАЛЫХ РАЗМЕРОВ В ЗАВИСИМОСТИ ОТ ВИДА ТЕРАПИИ ПЕРВИЧНОЙ ОПУХОЛИ

Authors: L. V. Naumenko, S. A. Krasny, K. P. Zhylayeva, A. A. Evmenenko, I. Y. Zherko, Л. В. Науменко, С. А. Красный, Е. П. Жиляева, А. А. Евмененко, И. Ю. Жерко

Source: Siberian journal of oncology; Том 20, № 5 (2021); 108-114 ; Сибирский онкологический журнал; Том 20, № 5 (2021); 108-114 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2021-20-5

Subject Terms: органосохраняющее лечение, uveal melanoma, transpupillary thermotherapy, photodynamic therapy, brachytherapy, metastatic-free survival, organ-preserving treatment, транспупиллярная термотерапия, фотодинамическая терапия, брахитерапия, безметастатическая выживаемость

File Description: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/1924/920; Murray T.G., Markoe A.M., Gold A.S., Ehlies F., Bermudez E., Wildner A., Latiff A. Long-term followup comparing two treatment dosing strategies of (125) I plaque radiotherapy in the management of small/ medium posterior uveal melanoma. J Ophthalmol. 2013; 2013: 517032. doi:10.1155/2013/517032.; Souto E.B., Zielinska A., Luis M., Carbone C., Martins-Gomes C., Souto S.B., Silva A.M. Uveal melanoma: physiopathology and new in situspecific therapies. Cancer Chemother Pharmacol. 2019 Jul; 84(1): 15–32. doi:10.1007/s00280-019-03860-z.; Krantz B.A., Dave N., Komatsubara K.M., Marr B.P., Carvajal R.D. Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 2017 Jan 31; 11: 279–289. doi:10.2147/OPTH. S89591.; Carvajal R.D., Schwartz G.K., Tezel T., Marr B., Francis J.H., Nathan P.D. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017; 101(1): 38–44. doi:10.1136/bjophthalmol-2016-309034.; Rodríguez-Cerdeira C., Carnero Gregorio M., López-Barcenas A., Sánchez-Blanco E., Sánchez-Blanco B., Fabbrocini G., Bardhi B., Sinani A., Guzman R.A. Advances in Immunotherapy for Melanoma: A Comprehensive Review. Mediators Inflamm. 2017; 2017: 3264217. doi:10.1155/2017/3264217.; Chi M., Dudek A.Z. Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials. Melanoma Res. 2011 Jun; 21(3): 165–74. doi:10.1097/CMR.0b013e328346554d.; Shields C.L., Shields J.A., Perez N., Singh A.D., Cater J. Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations. Ophthalmology. 2002 Feb; 109(2): 225–34. doi:10.1016/s0161-6420(01)00902-2.; Stoffelns B.M., Schoepfer K., Vetter J., Mirshahi A., Elflein H. Long-term follow-up 10 years after transpupillary thermotherapy (TTT) for small, posterior located malignant melanomas of the choroid. Klin Monbl Augenheilkd. 2011 Apr; 228(4): 277–83. doi:10.1055/s-0031-1273207.; Yarovoy A.A., Magaramov D.A., Bulgakova E.S. Which choroidal melanoma should be treated with primary transpupillary thermotherapy? Our experience from 78 patients. Eur J Ophthalmol. 2010 Jan-Feb; 20(1): 186–93. doi:10.1177/112067211002000126.; Fabian I.D., Stacey A.W., Harby L.A., Arora A.K., Sagoo M.S., Cohen V.M.L. Primary photodynamic therapy with verteporfin for pigmented posterior pole cT1a choroidal melanoma: a 3-year retrospective analysis. Br J Ophthalmol. 2018 Dec; 102(12): 1705–1710. doi:10.1136/bjophthalmol-2017-311747.; Campbell W.G., Pejnovic T.M. Treatment of amelanotic choroidal melanoma with photodynamic therapy. Retina. 2012 Jul; 32(7): 1356–62. doi:10.1097/IAE.10.1097/IAE.0b013e31822c28ec.; Shields C.L., Sioufi K., Srinivasan A., Di Nicola M., Masoomian B., Barna L.E., Bekerman V.P., Say E.A.T., Mashayekhi A., Emrich J., Komarnicky L., Shields J.A. Visual Outcome and Millimeter Incremental Risk of Metastasis in 1780 Patients With Small Choroidal Melanoma Managed by Plaque Radiotherapy. JAMA Ophthalmol. 2018 Dec 1; 136(12): 1325‒1333. doi:10.1001/jamaophthalmol.2018.3881.; Науменко Л.В., Красный С.А., Жиляева Е.П., Евмененко А.А., Сущеня Г.А. Энуклеация или органосохраняющая методика лечения меланомы сосудистой оболочки глаза? Известия Национальной академии наук Беларуси. Серия медицинских наук. 2020; 17(3): 320–328. doi:10.29235/1814-6023-2020-17-3-320-328.; Науменко Л.В. Транспупиллярная термотерапия меланомы сосудистой оболочки глаза. Biomedical Photonics. 2020; 9(2): 29 2013–35. doi:10.24931/2413-9432-2020-9-2-29-35.; Kaliki S., Shields C.L., Shields J.A. Uveal melanoma: estimating prognosis. Indian J Ophthalmol. 2015; 63(2): 93–102. doi:10.4103/0301-4738.154367.; Augsburger J.J., Corrêa Z.M., Augsburger B.D. Frequency and implications of discordant gene expression profile class in posterior uveal melanomas sampled by fine needle aspiration biopsy. Am J Ophthalmol. 2015 Feb; 159(2): 248–56. doi:10.1016/j.ajo.2014.10.026.; Corrêa Z.M., Augsburger J.J. Independent Prognostic Significance of Gene Expression Profile Class and Largest Basal Diameter of Posterior Uveal Melanomas. Am J Ophthalmol. 2016 Feb; 162: 20–27.e1. doi:10.1016/j.ajo.2015.11.019.; Walter S.D., Chao D.L., Feuer W., Schiffman J., Char D.H., Harbour J.W. Prognostic Implications of Tumor Diameter in Association With Gene Expression Profile for Uveal Melanoma. JAMA Ophthalmol. 2016 Jul 1; 134(7): 734–40. doi:10.1001/jamaophthalmol.2016.0913.; https://www.siboncoj.ru/jour/article/view/1924

Availability: https://www.siboncoj.ru/jour/article/view/1924
https://doi.org/10.21294/1814-4861-2021-20-5-108-114

First experience of superselective embolization of renal arteries supplying the tumor with subsequent laparoscopic kidney resection ; Первый опыт суперселективной эмболизации артерий, кровоснабжающих опухоль, с последующей лапароскопической резекцией почки

Authors: V. L. Astashov, V. V. Shapovalov, V. V. Balanyuk, A. I. Zagorul’ho, D. V. Kozlov, M. A. Andreeva, O. R. Sinitsyna, A. S. Radomskiy, В. Л. Асташов, В. В. Шаповалов, В. В. Баланюк, А. И. Загорулько, Д. В. Козлов, М. А. Андреева, О. Р. Синицына, А. С. Радомский

Source: Cancer Urology; Том 17, № 3 (2021); 30-36 ; Онкоурология; Том 17, № 3 (2021); 30-36 ; 1996-1812 ; 1726-9776

Subject Terms: ишемия почки, organ-sparing treatment, X-ray endovascular surgery, superselective renal artery embolization, kidney ischemia, органосохраняющее лечение, рентгенэндоваскулярная хирургия, суперселективная эмболизация почечной артерии

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1450/1296; Thompson R.H., Lane B.R., Lohse C.M. et al. Every minute counts when the renal hilum is clamped during partial nephrectomy. Eur Urol 2010;58(3):340—5. DOI:10.1016/j.eururo.2010.05.047.; Gong E.M., Zorn K.C., Orvieto M.A. et al. Artery-only occlusion may provide superior renal preservation during laparoscopic partial nephrectomy. Urology 2008;72(4):843—6. DOI:10.1016/j.urology.2008.05.020.; Limtrakul T., Rompsaithong U., Ahooja A. et al. Renal artery embolization for acute renal hemorrhage: a single-center experience. Res Rep Urol 2020;12:315-9. DOI:10.2147/RRU.S263012.eCollection 2020.; Li D., Pua B.B., Madoff D.C. Role of embolization in the treatment of renal masses. Semin Intervent Radiol 2014;31(1):70—81. DOI:10.1055/s-0033-1363845.; Аляев Ю.Г., Сорокин Н.И., Кондра-шин С.А. и др. Суперселективная эмболизация сосудов, питающих опухоль, перед резекцией почки. Вестник урологии 2016;(2):13—27.; Cadeddu J.A. Zero ischemia laparoscopic partial nephrectomy after superselective transarterial tumor embolization for tumors with moderate nephrometry score: long-term results of a single-center experience. J Urol 2012;187(4):1226. DOI:10.1016/jjuro.2011.12.031.; https://oncourology.abvpress.ru/oncur/article/view/1450

Availability: https://oncourology.abvpress.ru/oncur/article/view/1450

Principles of radiotherapy for laryngeal cancer ; Принципы лучевой терапии рака гортани

Authors: S. B. Alieva, R. I. Azizyan, A. M. Mudunov, I. A. Zaderenko, N. A. Daykhes, V. Z. Dobrokhotova, E. N. Novozhilova, S. S. Reshulskiy, T. N. Borisova, V. V. Vinogradov, С. Б. Алиева, Р. И. Азизян, А. М. Мудунов, И. А. Задеренко, Н. А. Дайхес, В. З. Доброхотова, Е. Н. Новожилова, С. С. Решульский, Т. Н. Борисова, В. В. Виноградов

Source: Head and Neck Tumors (HNT); Том 11, № 1 (2021); 24-33 ; Опухоли головы и шеи; Том 11, № 1 (2021); 24-33 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2021-11-1

Subject Terms: органосохраняющее лечение, radiation therapy, organ-preservation therapy, лучевая терапия

File Description: application/pdf

Relation: https://ogsh.abvpress.ru/jour/article/view/608/460; Mendenhall W.M., Werning J.W., Hinerman R.W. et al. Management of T1-T2 glottic carcinomas. Cancer 2004;100:1786-92. DOI:10.1002/cncr.20181.; Chera B.S., Amdur R.J., Morris C.G. et al. T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 2010;78:461-6. DOI:10.1016/j.ijrobp.2009.08.066.; Пачес А.И. Опухоли головы и шеи. М.: Медицина, 2001.; Lederman M. The place of radiotherapy in the treatment of cancer of the larynx. Ann Radiol (Paris) 1961;4:433-54. DOI:10.1136/bmj.1.5240.1639.; The International Commission on Radiation Units and Measurements. J ICRU 2010;10(2):5—6. DOI:10.1093/jicru/ndq025.; Yamazaki H., Suzuki G., Nakamura S. et al. Radiotherapy for laryngeal cancer — technical aspects and alternate fractionation. J Radiat Res 2017;58(4):495—508. DOI:10.1093/jrr/rrx023.; Chera B.S., Amdur R.J., Morris C.G. et al. T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 2010;78(2):461-6. DOI:10.1016/j.ijrobp.2009.08.066.; Tamura Y., Tanaka S., Asato R. et al. Therapeutic outcomes of laryngeal cancer at Kyoto University Hospital for 10 years. Acta Otolaryngol Suppl 2007;(557):62—5. DOI:10.1080/00016480601067990.; Blanch J.L., Vilaseca I., Caballero M. et al. Outcome of transoral laser microsurgery for T2-T3 tumors growing in the laryngeal anterior commissure. Head Neck 2011;33(9):1252-9. DOI:10.1002/hed.21605.; Aaltonen L.M., Rautiainen N., Sellman J. et al. Voice quality after treatment of early vocal cord cancer: a randomized trial comparing laser surgery with radiation therapy. Int J Radiat Oncol Biol Phys 2014;90(2):255-60. DOI:10.1016/j.ijrobp.2014.06.032.; Higgins K.M., Shah M.D., Ogaick M.J., Enepekides D. Treatment of early-stage glottic cancer: meta-analysis comparison of laser excision versus radiotherapy. J Otolaryngol Head Neck Surg 2009;38(6):603. DOI:10.2310/7070.2009.080235.; Amdur R.J., Parsons J.T., Mendenhall W.M. et al. Postoperative irradiation for squamous cell carcinoma of the head and neck: an analysis of treatment results and complications. Int J Radiat Oncol Biol Phys 1989;16:25-36. DOI:10.1016/0360-3016(89)90006-0.; Wolf G.Y., Fisher S.G., Hong W.K. et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324(24):1685-90. DOI:10.1016/0196-0709(91)90133-z.; Forastiere A.A., Goepfert H., Maor M. et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349(22):2091-8.; Mendenhall W.M., Amdur R.J., Morris C.G. et al. T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol 2001;19:4029-36. DOI:10.1200/jco.2001.19.20.4029.; Yamazaki H., Nishiyama K., Tanaka E. et al. Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys 2006;64:77-82.; Megan E.D., Le Q.T., Jain A.K. et al. Intensity-modulated radiotherapy for locally advanced cancers of the larynx and hypopharynx. Head Neck 2011;33:103-11. DOI:10.1016/j.ijrobp.2005.06.014.; Practical Radiation Oncology. Ed. by S. Mallick, G.K. Rath, R. Benson. Singapore: Springer, 2020. 300 p. DOI:10.1007/978-981-15-0073-2.; Mendenhall W.M., Riggs C.E., Cassisi N.J. Treatment of head and neck cancers. In: DeVita, Hellman, and Rosenberg’s Cancer: principles and practice of oncology. Ed. by V.T. DeVita, S. Hellman, S.A. Rosenberg. Philadelphia: Lippincott Williams & Wilkins, 2008. Pp. 809-814. DOI:10.1007/3-540-35665-7_18.; Gourin C.G., Conger B.T., Sheils W.C. et al. The effect of treatment on survival in patients with advanced laryngeal carcinoma. Laryngoscope 2009;119:1312-7. DOI:10.1002/lary.20477.; Hinerman R.W., Mendenhall W.M., Amdur R.J. et al. Carcinoma of the supraglottic larynx: treatment results with radiotherapy alone or with planned neck dissection. Head Neck 2002;24:456-67. DOI:10.1002/hed.10069.; Bernier J., Cooper J.S., Pajak T.F. et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 2005;27(10):843-50. DOI:10.1002/hed.20279.; Cooper J.S., Zhang O., Pajak T.F. et al. Long-term follow-up of the RTOG 9501/ intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2012;84(5):1198—205. DOI:10.1016/j.ijrobp.2012.05.008.; Amdur R.J., Parsons J.T., Mendenhall WM. et al. Postoperative irradiation for squamous cell carcinoma of the head and neck: an analysis of treatment results and complications. Int J Radiat Oncol Biol Phys 1989;16:25-36. DOI:10.1016/0360-3016(89)90006-0.; Forastiere A.A., Zhang Q., Weber R.S. et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013;31(7):845-52. DOI:10.1200/jco.2012.43.6097.; Hoffman H.T., Porter K., Karnell L.H. et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006;116:1-13. DOI:10.1097/01.mlg.0000236095.97947.26.; Dziegielewski P.T., O’Connell D.A., Klein M. et al. Primary total laryngectomy versus organ preservation for T3/T4a laryngeal cancer: a population-based analysis of survival. J Otolaryngol Head Neck Surg 2012;41 Suppl 1:S56-64. DOI:10.2310/7070.2011.110081.; Megwalu U.C., Sikora A.G. Survival outcomes in advanced laryngeal cancer. JAMA Otolaryngol Head Neck Surg 2014;140:855-60. DOI:10.1001/jamaoto.2014.1671.; Ткачев С.И., Матякин Е.Г., Любаев В.Л. и др. Сравнительная оценка пятилетних результатов хирургического, комбинированного, лучевого и химиолучевого методов лечения рака гортани в стадии T3N0M0. Вопросы онкологии 2006;52(4):404-8.; Mendenhall W.M., Morris C.G.,Amdur R.J. et al. Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head Neck 2003;25:535-42. DOI:10.1002/hed.10253.; Клинические рекомендации по лечению опухолей гортани под редакцией Ассоциации онкологов России и Российского общества специалистов по опухолям головы и шеи. Доступно по: https://oncology-association.ru/files/clinical-guidelines-2020/Rak_gortani.pdf.; Specenier P., Vermorken J.B Cetuximab: its unique place in head and neck cancer treatment. Biologics 2013;7:77-90. DOI:10.2147/btt.s43628.; Al-Othman M.O., Amdur R.J., Morris C.G. et al. Does feeding tube placement predict for long-term swallowing disability after radiotherapy for head and neck cancer? Head Neck 2003;25:741-7. DOI:10.1002/hed.10279.; https://ogsh.abvpress.ru/jour/article/view/608

Availability: https://ogsh.abvpress.ru/jour/article/view/608
https://doi.org/10.17650/2222-1468-2021-11-1-24-33

Organ-Preserving Surgery in Urethral Cancer (a Clinical Case) ; Органосохраняющее хирургическое лечение при раке мочеточника (клинический случай)

Authors: N. S. Kholopova, V. B. Venskel, N. V. Kovalenko, V. V. Zhavoronkova, A. I. Ivanov, A. G. Chuhnin, A. A. Klimchenko, Н. С. Холопова, В. Б. Венскель, Н. В. Коваленко, В. В. Жаворонкова, А. И. Иванов, А. Г. Чухнин, А. А. Климченко

Source: Creative surgery and oncology; Том 11, № 4 (2021); 323-327 ; Креативная хирургия и онкология; Том 11, № 4 (2021); 323-327 ; 2076-3093 ; 2307-0501

Subject Terms: лапароскопия, urethral cancer, low-grade malignancy, transitional cell carcinoma, organ-preserving treatment, laparoscopy, рак мочеточника, низкая степень злокачественности, переходно-клеточная карцинома, органосохраняющее лечение

File Description: application/pdf

Relation: https://www.surgonco.ru/jour/article/view/636/472; Уротелиальный рак верхних мочевыводящих путей: Клинические рекомендации: МКБ С65, С66. Возрастная группа: взрослые, дети. М., 2020.; Тайлаков Б.Б., Давранов А.Ж., Алибекова Б.С., Абдикаримов А.М., Рутжанулы И. Хирургическая тактика при злокачественных опухолях верхних мочевыводящих путей. Вестник Алматинского государственного института усовершенствования врачей. 2014; 3:179–81.; Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2020 году. М.: МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИЦ радиологии», 2020.; Geavlete P.A. (ed.) Percutaneos surgery of the upper urinary tract. Handbook of endourology. Elsevier; 2016.; Боковой С.П., Зверев Ю.А. Опухоли мочеточника. Сложные клинические случаи. Урологические ведомости. 2019;9(2):47–52. DOI:10.17816/uroved9247-52; Geavlete P.A. (ed.) Retrograde ureteroscopy. Handbook of endourology. Elsevier; 2018.; Нестеров С.Н., Ханалиев Б.В., Косарев Е.И., Бонецкий Б.А., Барсегян А.Г. Васкуляризированные кожные лоскуты при пластике гипоспадий, протяженных стриктур и облитераций уретры у мужчин. Вестник НМХЦ им. Н.И. Пирогова. 2018;3(13):50–4. DOI:10.25881/BPNMSC.2018.96.68.011; Kim M.H., Yuk H.D., Jeong C.W., Kwak C., Kim H.H., Ku J.H. Estimated glomerular fi ltration rate as a prognostic factor in urothelial carcinoma of the upper urinary tract: a systematic review and metaanalysis. J Clin Med. 2021;10(18):4155. DOI:10.3390/jcm10184155; Soualhi A., Rammant E., George G., Russell B., Enting D., Nair R., et al. Th e incidence and prevalence of upper tract urothelial carcinoma: a systematic review. BMC Urol. 2021;21(1):110. DOI:10.1186/s12894- 021-00876-7; Волкова М.И., Матвеев В.Б., Медведев С.В., Носов Д.А., Хмелевский Е.В., Черняев В.А. Клинические рекомендации по диагностике и лечению больных с опухолями верхних мочевыводящих путей. М., 2014.; Zhao F., Qi N., Zhang C., Xue N., Li S., Zhou R., et al. Impact of surgical wait time on survival in patients with upper urinary tract urothelial carcinoma with hydronephrosis. Front Oncol. 2021 5;11:698594. DOI:10.3389/fonc.2021.698594; Farrow J.M., Kern S.Q., Gryzinski G.M., Sundaram C.P. Nephronsparing management of upper tract urothelial carcinoma. Investig Clin Urol. 2021;62(4):389–98. DOI:10.4111/icu.20210113; Kenigsberg A.P., Meng X., Ghandour R., Margulis V. Oncologic outcomes of radical nephroureterectomy (RNU). Transl Androl Urol. 2020;9(4):1841–52. DOI:10.21037/tau.2019.12.29; Seisen T., Peyronnet B., Dominguez-Escrig J.L., Bruins H.M., Yuan C.Y., Babjuk M., et al. Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU non-muscle invasive bladder cancer guidelines panel. Eur Urol. 2016;70(6):1052–68. DOI:10.1016/j. eururo.2016.07.014; Wang M., Ren X., Wang G., Sun X., Tang S., Zhang B., et al. Construction of a survival prediction model for high-and low -grade UTUC aft er tumor resection based on “SEER database”: a multicenter study. BMC Cancer. 2021;21(1):999. DOI:10.1186/s12885-021-08742-3; https://www.surgonco.ru/jour/article/view/636

Availability: https://www.surgonco.ru/jour/article/view/636
https://doi.org/10.24060/2076-3093-2021-11-4-323-327

New opportunities for the staging of cervical cancer with the use of routine hemostatic parameters ; Новые возможности стадирования рака шейки матки с использованием рутинных показателей гемостаза

Authors: Stuklov N.I., Sushinskaya T.V., Alexandrova M.R.

Source: Вестник последипломного медицинского образования

Subject Terms: система гемостаза, hemostasis, gynecological cancer patients with cervical cancer, Stage of disease, disorders of hemostasis, fibrinogen, soluble fibrin-Monomeric complexes, organ-saving treatment, рак шейки матки, онкогинекологические больные, стадии заболевания, нарушения гемостаза, фибриноген, растворимые фибрин-мономерные комплексы, органосохраняющее лечение

Relation: https://openrepository.ru/article?id=245200

Availability: https://openrepository.ru/article?id=245200

Bladder cancer: what’s new in 2019—2020 ; Рак мочевого пузыря: что нового в 2019-2020 гг.

Authors: O. B. Karyakin, О. Б. Карякин

Source: Cancer Urology; Том 16, № 4 (2020); 147-154 ; Онкоурология; Том 16, № 4 (2020); 147-154 ; 1996-1812 ; 1726-9776

Subject Terms: консенсусное мнение, morphology, intravesical chemotherapy, organ-sparing treatment, immunotherapy, complication of surgical treatment, COVID-19, consensus opinion, морфология, внутрипузырная химиотерапия, органосохраняющее лечение, иммунотерапия, осложнение хирургического лечения

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1351/1225; Kamoun A, De Reyniès A, Allory Y, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2020 June; 77(4):420-423. DOI:10.1016/j.eururo.2019.09.006.; Yanagisawa T, Miki J, Sakanaka K, et al. MP73-03 clinical significance of horizontal and vertical margin of OF EN-BLOC TURBT specimen. J Urol. 2020 April; 203:1121-1122. DOI:10.1097/JU.0000000000000959.03.; Sathianathen N, Gantz J, Alarid-Escudero F, et al. MP73-07 intravesical chemotherapy for low grade bladder cancer: a cost analysis. J Urol. 2020 April; 203:1123-1124. DOI:10.1097/JU.0000000000000959.07; Adele Caruso A, Ravishankar R, VanArsdalen K, et al. MP73-08 intravesical gemcitabine and docetaxol in heavily PRE-TREATED patients with non-muscle invasive bladder cancer (NMIBC). J Urol. 2020 April; 203:1123-1124. DOI:10.1097/JU.0000000000000959.08; Herr H. PD51-04 bladder – sparing surgery (BSS) for muscle invasive bladder cfncer (MIBC) after complete response to neoadjuvant chemotherapy (NAC). J Urol. 2020 April; 203:1084. DOI:10.1097/JU.0000000000000953.04; Kool R, Marcq G, Busca J, et al. PD60-01 definitive radiation-based therapy for muscle-invasive bladder cancer: the Canadian multicenter experience. J Urol. 2020 April; 203:1273. DOI:10.1097/JU.0000000000000977.01.; Shou J, Cao C, Jiang W, et al. PD51-07 oncologic and functional effectiveness of neoadjuvant chemotherapy followed by surgery plus concurrent chemoradiotherapy or cystectomy for muscle-invasive bladder cancer: preliminary results of a prospective phase II stude. J Urol. 2020 April; 203:1085. DOI:10.1097/JU.0000000000000953.07).; Nathan Suskovic N, Raldow A, Royce T, et al. PD55-03 cost-effectiveness of radical cystectomy vs. Trimodality therapy for muscle-invasive bladder cancer. J Urol. 2020 April; 203:1182-1183. DOI:10.1097/JU.0000000000000965.03).; European Association of Urology. Guidelines 2020 edition.; Elsayed A, Zhe Jing Z, Osei J, et al. PD55-10 outcomes of robot-assisted radical cystectomy in North America vs Europe: results from the international robotic cystectomy consortium. J Urol. 2020 April; 203:1186. DOI:10.1097/JU.0000000000000965.010).; Vuky J, Balar AV, Castellano D, et al. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. Jour. Clin. Onc. 2020 August,38 (23):2658-2666. Doi.org/10.1200/JCO.19.01213).; Grivas P, Plimack ER, Balar AV, et al. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status. Eur Urol Onc. 2020 June, 3 (3):351. DOI.org/10.1016/j.euo.2020.02.009).; Necchi A, Raggi D, Bandini M, et al. PD51-01 interim results of PEANUT: an open-label, single-arm, phase 2 study evaluating pembrolizumab plus nanoparticle albumin-bound paclitaxel (nab- paclitaxel) fs salvage therapy for metastatic urothelial carcinoma (UC). J Urol. 2020 April; 203:1083. DOI:10.1097/JU.0000000000000953.01.; Biyani CS, Pecanka J, Rouprêt M, et al. Intraoperative Adverse Incident Classification (EAUiaiC) by the European Association of Urology ad hoc Complications Guidelines Panel. Eur Urol. 2020 May.77 (5):601-610. DOI.org/10.1016/j.eururo.2019.11.015.; Gillessen S, Powles T. Advice Regarding Systemic Therapy in Patients with Urological Cancers During the COVID-19 Pandemic. Eur Urol. 2020 June. 77 (6):667-668. DOI.org/10.1016/j.eururo.2020.03.026; Stensland KD, Morgan TM, Moinzadeh A, et al. Considerations in the Triage of Urologic Surgeries During the COVID-19 Pandemic. Eur Urol, 2020 Apr, 77(6):663-666. DOI.org/10.1016/j.eururo.2020.03.027; Witjes JA, Babjuk M, Bellmunt J, et al. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort† : Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol. 2020 February. 77(2): 223-250. DOI.org/10.1016/j.eururo.2019.09.035.; https://oncourology.abvpress.ru/oncur/article/view/1351

Availability: https://oncourology.abvpress.ru/oncur/article/view/1351
https://doi.org/10.17650/1726-9776-2020-16-4-147-154

Semiotics and the role of transrectal ultrasound in rectal cancer staging ; Семиотика и роль трансректального ультразвукового исследования в стадировании рака прямой кишки

Authors: A. A. Demidova, Z. M. Abdulatipova, A. B. Baychorov, A. V. Leontyev, G. G. Saakyan, M. A. Danilov, А. А. Демидова, З. М. Абдулатипова, А. Б. Байчоров, А. В. Леонтьев, Г. Г. Саакян, М. А. Данилов

Source: Surgery and Oncology; Том 10, № 3-4 (2020); 84-91 ; Хирургия и онкология; Том 10, № 3-4 (2020); 84-91 ; 2949-5857

Subject Terms: органосохраняющее лечение, endorectal ultrasound, staging, organ-preserving treatment, трансректальное ультразвуковое исследование, стадирование

File Description: application/pdf

Relation: https://www.onco-surgery.info/jour/article/view/488/355; Glynne-Jones R., Wyrwicz L. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(Suppl 4): iv22–40. DOI:10.1093/annonc/mdx224.; Taylor F.G., Swift R.I., Blomqvist L. et al. A systematic approach to the interpretation of preoperative staging MRI for rectal cancer. Am J Roentgenol 2008; 191:1827–35. DOI:10.2214/AJR.08.1004.; Bipat S., Glas A.S., Slors F.J. et al. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging – a meta-analysis. Radiology 2004;232(3):773–83. DOI:10.1148/radiol.2323031368.; Tombazzi C.R., Loy P., Bondar V. et al. Accuracy of endoscopic ultrasound in staging of early rectal cancer. Fed Pract 2019;36(Suppl 5):S26–9.; Haggitt R.C., Glotzbach R.E., Soffer E.E., Wruble L.D. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology 1985;89:328–36.; Kikuchi R., Takano M., Takagi K. et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. Dis Colon Rectum 1995;38(12):1286–95. DOI:10.1007/BF02049154.; Bach S.P., Hill J., Monson J.R. et al. A predictive model for local recurrence after transanal endoscopic microsurgery for rectal cancer. Br J Surg 2009;96:280–90. DOI:10.1002/bjs.6456.; Junginger T., Goenner U., Hitzler M. et al. Long-term oncologic outcome after transanal endoscopic microsurgery for rectal carcinoma. Dis Colon Rectum 2016;59:8–15. DOI:10.1097/DCR.0000000000000509.; Stornes T., Wibe A., Nesbakken A. et al. National early rectal cancer treatment revisited. Dis Colon Rectum 2016;59: 623–9. DOI:10.1097/DCR.0000000000000591.; Nascimbeni R., Burgart L.J., Nivatvongs S., Larson D.R. Risk of lymph node metastasis in Tl carcinoma of the colon and rectum. Dis Colon Rectum 2002;45(2):200–6.; Takayuki A., Hitoshi K. Endorectal ultrasonography and treatment of early stage rectal cancer. World J Surg 2000;24:1061–8.; Ассоциация колопроктологов России. Клинические рекомендации. 2017 г.; Iafrate F., Laghi A., Paolantonio P. et al. Preoperative staging of rectal cancer with MR Imaging: correlation with surgical and histopathologic findings. Radiographics 2006;26(3):701–14. DOI:10.1148/rg.263055086.; Diop M., Parratte B., Tatu L. et al. “Mesorectum”: the surgical value of an anatomical approach. Surg Radiol Anat 2003;25(3–4):290–304.; Kim M.J. Transrectal ultrasonography of anorectal diseases: advantages and disadvantages. Ultrasonography 2015;34(1):19–31.; Krajewski K.M., Kane R.A. Ultrasound staging of rectal cancer. Seminars in Ultra sound, CT and MRI. 2008. Pp. 428–432.; Puli S.R., Bechtold M.L., Reddy J.B. et al. How good is endoscopic ultrasound in differentiating various T stages of rectal cancer? Meta-analysis and systematic review. Ann Surg Oncol 2009;16(2):254–65. DOI:10.1245/s10434-008-0231-5.; Ashraf S., Hompes R. A critical appraisal of endorectal ultrasound and transanal endoscopic microsurgery and decisionmaking in early rectal cancer. The Association of Coloproctology of Great Britain and Ireland, 2011. Pp. 821–827.; Ruediger S. Impact of biopsy on the accuracy of endorectal ultrasound staging of rectal tumors. ASCRS, 2008. Pp. 1125–1128.; Serra-Aracil X., Galvez A., Mora L. et al. Endorectal ultrasound in the identification of rectal tumors for transanal endoscopic surgery: factors influencing its accuracy. Surgical Endosc 2017;32:8. DOI:10.1007/s00464-017-5988-9; Badger S.A., Devlin P.B., Neilly P.J. et al. Preoperative staging of rectal carcinoma by endorectal ultrasound: is there a learning curve? Int J Colorectal Dis 2007;22:1261–8. DOI:10.1007/s00384-007-0273-3.; Santoro G.A., Gizzi G., Pellegrini L. et al. The value of high-resolution three-dimensional endorectal ultrasonography in the management of submucosal invasive rectal tumors, santo et al: three-dimensional ultrasound of submucosal tumors. Dis Colon Rect 2009;52(11):1837–43.; Ren Y., Ye J., Wang Y. et al. The optimal application of transrectal ultrasound in staging of rectal cancer following neoadjuvant therapy: a pragmatic study for accuracy investigation. J Cancer 2018;9(5):784–91. DOI:10.7150/jca.22661.; Leon-Carlyle M., Brown A.J. The accuracy of endorectal ultrasound in staging rectal lesions in patients undergoing transanal endoscopic microsurgery. Am J Surg 2016;212(3):455–60. DOI:10.1016/j.amjsurg.2015.10.018.; Badger S.A., Devlin P.B., Neilly P.J.D. et al. Preoperative staging of rectal carcinoma by endorectal ultrasound: is there a learning curve? Int J Colorectal Dis 2007;22(10):1261–8. DOI:10.1007/s00384-007-0273-3.; Oien K., Forsmo H.M., Rosler C. et al. Endorectal ultrasound and magnetic resonance imaging for staging of early rectal cancers: how well does it work in practice. Acta Oncol 2019; 58(Suppl 1):S49–54. DOI:10.1080/0284186X.2019.1569259.; Ye D., Zhu Zh., Chen F. et al. Correlation between endorectal ultrasound and magnetic imaging for predicting the circumferential resection margin in patients with mid-low rectal cancer without preoperative chemoradiotherapy. J Ultrasound Med 2020;39(3):569–77. DOI:10.1002/jum.15135.; Patel R.K., Sayers A.E., Kumar P. et al. The role of endorectal ultrasound and magnetic resonance imaging in the management of early rectal lesions in a tertiary center. Clin Colorectal Cancer 2014;13:245–50.

Availability: https://www.onco-surgery.info/jour/article/view/488
https://doi.org/10.17650/2686-9594-2020-10-3-4-84-91